WO2009156151A1 - Mesoangioblast-like cell as well as methods and uses relating thereto - Google Patents
Mesoangioblast-like cell as well as methods and uses relating thereto Download PDFInfo
- Publication number
- WO2009156151A1 WO2009156151A1 PCT/EP2009/004584 EP2009004584W WO2009156151A1 WO 2009156151 A1 WO2009156151 A1 WO 2009156151A1 EP 2009004584 W EP2009004584 W EP 2009004584W WO 2009156151 A1 WO2009156151 A1 WO 2009156151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- mesoangioblast
- subject
- cells
- hgf
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 210000004027 cell Anatomy 0.000 claims abstract description 450
- 210000003716 mesoderm Anatomy 0.000 claims abstract description 25
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 20
- 208000023589 ischemic disease Diseases 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 77
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 77
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 62
- 230000014509 gene expression Effects 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 48
- 239000008280 blood Substances 0.000 claims description 48
- 229920000669 heparin Polymers 0.000 claims description 48
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 47
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 47
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 47
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 46
- 230000004069 differentiation Effects 0.000 claims description 45
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 43
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 42
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 42
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 37
- 229960002897 heparin Drugs 0.000 claims description 36
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 30
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 23
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 22
- 230000003028 elevating effect Effects 0.000 claims description 22
- 230000037396 body weight Effects 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 20
- 208000010125 myocardial infarction Diseases 0.000 claims description 20
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 19
- 102100032912 CD44 antigen Human genes 0.000 claims description 18
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 18
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 210000002889 endothelial cell Anatomy 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 17
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 15
- 102100040120 Prominin-1 Human genes 0.000 claims description 15
- 108010017842 Telomerase Proteins 0.000 claims description 14
- 239000003055 low molecular weight heparin Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 11
- 102100025304 Integrin beta-1 Human genes 0.000 claims description 11
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 10
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 10
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 102100022749 Aminopeptidase N Human genes 0.000 claims description 8
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 8
- 101150037203 Sox2 gene Proteins 0.000 claims description 8
- 102100037241 Endoglin Human genes 0.000 claims description 7
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 claims description 6
- 210000000963 osteoblast Anatomy 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000002792 vascular Effects 0.000 claims description 5
- -1 CD 144 Proteins 0.000 claims description 4
- 102100029761 Cadherin-5 Human genes 0.000 claims description 4
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 8
- 210000000130 stem cell Anatomy 0.000 description 52
- 230000000747 cardiac effect Effects 0.000 description 35
- 239000003550 marker Substances 0.000 description 32
- 238000003757 reverse transcription PCR Methods 0.000 description 29
- 230000003511 endothelial effect Effects 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000000338 in vitro Methods 0.000 description 21
- 210000002216 heart Anatomy 0.000 description 20
- 210000000056 organ Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 17
- 230000002612 cardiopulmonary effect Effects 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 210000005259 peripheral blood Anatomy 0.000 description 16
- 239000011886 peripheral blood Substances 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 210000001671 embryonic stem cell Anatomy 0.000 description 15
- 210000005087 mononuclear cell Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 102000004987 Troponin T Human genes 0.000 description 14
- 108090001108 Troponin T Proteins 0.000 description 14
- 230000001976 improved effect Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 12
- 108010082117 matrigel Proteins 0.000 description 12
- 206010061216 Infarction Diseases 0.000 description 11
- 238000003501 co-culture Methods 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 230000003394 haemopoietic effect Effects 0.000 description 11
- 230000004217 heart function Effects 0.000 description 11
- 230000007574 infarction Effects 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 10
- 102000008790 VE-cadherin Human genes 0.000 description 10
- 108010018828 cadherin 5 Proteins 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 238000011580 nude mouse model Methods 0.000 description 10
- 230000002062 proliferating effect Effects 0.000 description 10
- 102100037362 Fibronectin Human genes 0.000 description 9
- 108010067306 Fibronectins Proteins 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 9
- 102000040945 Transcription factor Human genes 0.000 description 9
- 108091023040 Transcription factor Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 102000010825 Actinin Human genes 0.000 description 8
- 108010063503 Actinin Proteins 0.000 description 8
- 102000014736 Notch Human genes 0.000 description 8
- 108010070047 Notch Receptors Proteins 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 7
- 108010085238 Actins Proteins 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 210000001654 germ layer Anatomy 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- 210000002460 smooth muscle Anatomy 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- 229920002971 Heparan sulfate Polymers 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 101150114527 Nkx2-5 gene Proteins 0.000 description 6
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000003205 diastolic effect Effects 0.000 description 5
- 230000013020 embryo development Effects 0.000 description 5
- 230000009762 endothelial cell differentiation Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 201000002818 limb ischemia Diseases 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 102100031465 Hepatocyte growth factor activator Human genes 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 4
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 4
- 108010051583 Ventricular Myosins Proteins 0.000 description 4
- 101150109862 WNT-5A gene Proteins 0.000 description 4
- 102000043366 Wnt-5a Human genes 0.000 description 4
- 108700020483 Wnt-5a Proteins 0.000 description 4
- 230000001464 adherent effect Effects 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000003293 cardioprotective effect Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000000432 density-gradient centrifugation Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical group O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000001023 pro-angiogenic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 108010043026 HGF activator Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 3
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 229960003942 amphotericin b Drugs 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007675 cardiac surgery Methods 0.000 description 3
- 230000001625 cardiomyogenic effect Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 210000002253 embryonic cardiomyocyte Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229960001318 fondaparinux Drugs 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000009168 stem cell therapy Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108091008603 HGF receptors Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 108700003486 Jagged-1 Proteins 0.000 description 2
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical class OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100032702 Protein jagged-1 Human genes 0.000 description 2
- 108700037966 Protein jagged-1 Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000010370 cell cloning Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 150000002016 disaccharides Chemical group 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002064 heart cell Anatomy 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- 239000002628 heparin derivative Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000002894 multi-fate stem cell Anatomy 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000007542 postnatal development Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 230000006459 vascular development Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 108700001624 vesicular stomatitis virus G Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 101000903927 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Beta-galactosidase A Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241001579853 Cossus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000033763 Familial hyperaldosteronism type I Diseases 0.000 description 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101710085796 Hepatocyte growth factor activator Proteins 0.000 description 1
- 102400000044 Hepatocyte growth factor activator long chain Human genes 0.000 description 1
- 101800001080 Hepatocyte growth factor activator long chain Proteins 0.000 description 1
- 102400000040 Hepatocyte growth factor activator short chain Human genes 0.000 description 1
- 101800001745 Hepatocyte growth factor activator short chain Proteins 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101100257362 Homo sapiens SOX2 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000713880 Spleen focus-forming virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940090880 ardeparin Drugs 0.000 description 1
- 229940104697 arixtra Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000032341 cell morphogenesis Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940107792 certoparin Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 210000002358 circulating endothelial cell Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000000093 cytochemical effect Effects 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000017793 embryonic organ development Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229940087051 fragmin Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 201000011266 glucocorticoid-remediable aldosteronism Diseases 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000009067 heart development Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940095443 innohep Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 229960000899 nadroparin Drugs 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002355 open surgical procedure Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960004762 parnaparin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000003616 phosphatase activity assay Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960005496 reviparin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 101150115978 tbx5 gene Proteins 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- SYRHIZPPCHMRIT-UHFFFAOYSA-N tin(4+) Chemical compound [Sn+4] SYRHIZPPCHMRIT-UHFFFAOYSA-N 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
Definitions
- the present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject ' s blood, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell.
- stem cells have been hailed as the next major step in the battle against serious degenerative disorders, such as diabetes and cardiovascular diseases, and for some debilitating or lethal neurological diseases, such as Parkinson's and motor neuron disease. Medical researchers believe that stem cell therapy has the potential to dramatically change the treatment of human disease.
- the two broad types of mammalian stem cells are: embryonic stem cells that are found in blastocysts, and adult (or somatic) stem cells that are found in postnatal tissues. Although the number of human embryonic stem cell lines has increased considerably in the past years, few of these have been w ⁇ characterized, and large hurdles still need to be overcome to ensure safety and efficacy. These will require substantial further investment and research.
- stem cell research It is not the entire field of stem cell research, but the specific field of human embryonic stem cell research that is at the centre of an ethical debate.
- embryonic stem cells In contrast to embryonic stem cells, the use of adult (postnatal) or somatic stem cells is widely accepted from an ethnical point of view.
- a number of adult stem cell therapies already exist, particularly bone marrow transplants that are used to treat leukemia.
- medical researchers anticipate being able to use technologies derived from stem cell research to treat a wider variety of diseases including without limitation cancer. Parkinson's disease, spinal cord injuries, cardiovascular diseases and muscle damage, amongst a number of other impairments and conditions.
- stem cell therapy offers novel treatment options.
- Several types of adult stem cells including different subsets of bone marrow- derived and tissue-resident progenitor cells were shown to induce vasculogenesis and cardiomyogenesis (Beltrami et al.. Cell 1 14. 763-76 (2003). Orlic et al., Nature 410, 701-5 (2001)).
- the number, the proliferative capacity, and the angiogenic and cardiomyogenic potential of these progenitor cells are severely limited particularly in patients with cardiovascular diseases (Vasa et al., Circ Res 89, E 1-7 (2001)).
- these stem cells are to be isolated in a convenient, safe and economic manner. Additionally, it is preferred that these cells can be isolated from diseased patients, e.g. patients with cardiovascular diseases, particularly for allotransplantation.
- a first aspect of the invention relates to a mesoangioblast-like cell, obtained from a subject ' s blood, as a medicament.
- the subject is or has been exposed to hepatocyte growth factor (HGF) or an agent elevating the subject ' s HGF level, in order to increase the number of MAB-like cells in the subject ' s blood.
- HGF hepatocyte growth factor
- the marker profile of the novel cells is distinct from hematopoietic or mesenchymal stem cells, but resembles embryonic multipotent mesoangioblasts (MABs). Therefore, these cells have been designated with mesoangioblast-like cells (MAB-like cells).
- Mesoangioblasts (MAB) are vessel-associated cells identified during embryonic development. In contrast to hemangioblasts, MABs express mesenchymal (CD73) and endothelial markers, but lack the hematopoietic marker CD45.
- An MAB cell of the present invention is characterized by the presence of mesenchymal (e.g. CD73 and/or CD13) and endothelial (e.g. KDR. Tie2.
- MAB-like cells are characterized by the absence of CD45 and the presence of CD73 and KDR. Additionally, the cells express one or more stem cell markers (e.g. islet- 1) and are characterized by marked proliferative capacity and high telomerase activity at least at the beginning of their cultivation (e.g. until passage 30, 25, 20. 15, 10. especially until passage 15 or 10). Most preferably. MABs are characterized by the following marker profile:
- “'high proliferative activity” is meant a population doubling within at most 50 hr. preferably at most 40 hr. most preferably at most 35 hrs.
- MAB-like cells are multipotent and improve functional recovery after ischemia.
- examined cells were shown to be capable of differentiating into distinct cell lineages, particularly distinct cardiovascular cell lineages, especially all 3 distinct cardiovascular cell lineages in vitro and in vivo. Furthermore, they may secrete pro- angiogenic and cardioprotective factors, and mediate functional improvements after therapeutic administration in models of ischemia and infarction. Phenotypically. these blood-derived cells may represent a correlate of embryonic dorsal aorta-derived mesoangioblasts present after birth and in the adult. Preliminary studies in children with previous gender-mismatched bone marrow-transplantation suggest that these circulating mesoangioblast-like cells are non-bone marrow-derived.
- HGF a cytokine mediating mobilization of mesoangioblast-like cells into the peripheral blood not only offers the possibility to increase the number of circulating mesoangioblast-like cells, but opens up an avenue to generate patient-specific multipotent cells for therapeutic application in patients with cardiovascular disease.
- Inventors identified circulating MAB-like cells in children.
- Children-derived MAB-like cells showed vigorous proliferation capacity and high telomerase activity.
- the capacity of children-derived MAB-like cells to acquire a cardiomyogenic phenotype has also been tested and confirmed. It is also shown that children-derived MAB-like cells express cardiac-specific genes after co-culture with cardiomyocytes and improved cardiac function in vivo. Since MAB-like cells can be easily isolated and expanded from peripheral blood, these cells are suitable to augment cardiac repair, e.g. in children with heart failure.
- MAB-like cells may be also isolated from adults.
- the number and proliferative capacity of the cells is correlated with the donor age. but unexpectedly increased in patients undergoing extracorporal circulation.
- Hepatocyte growth factor (HGF) which is significantly elevated during extracorporal circulation, induces mobilization of mesoangioblast-like cells.
- HGF-mobilized clonally expandable, multipotent progenitor cells constitute a clinically useful source to generate subject- or patient-specific multipotent cells e.g. for therapeutic application in cardiovascular diseases.
- the MAB-like cells may be used as a medicament, which may optionally encompass excipients and/or auxiliaries. It should be noted that a sufficient amount of MAB-like cells should be present in the medicament. It is also possible to combine the cells of two or more subjects into one medicament.
- the number of MAB-like cells to be administered to a subject amounts to at least 10 Mio. more preferable at least 20 Mio. still more preferably at least 50 Mio MAB-like cells per treatment. It might be necessary to administer the MAB-like cells in several doses, e.g. on different days for successful treatment.
- the cells are propagated before administration.
- the MAB-like cells are preferably disaggregated into single clones which may be further expanded in e.g. liquid cultures containing suitable media, e.g. endothelial basal medium (EBM), X vivo 10 or X vivo 15 (e.g. from Biowhittaker). with supplements (e.g. hydrocortisone, bovine brain extract, antibiotics, growth factor(s) such as epidermal growth factor (EGF) or vascular endothelial growth factor (VEGF) and/or serum such as fetal calf serum, human serum or autologous serum).
- EBM epidermal growth factor
- VEGF vascular endothelial growth factor
- serum such as fetal calf serum, human serum or autologous serum.
- the MAB-like cells should be in a pharmaceutical dosage form in general consisting of a mixture of ingredients known to a skilled person in the pharmacotechnical arts such as pharmaceutically acceptable excipients and/or auxiliaries combined to provide desirable characteristics.
- examples of such substances are isotonic saline. Ringer's solution, buffers, medium (e.g. EBM. X vivo 10 and X vivo 15) organic or inorganic acids and bases as well as their salts and buffer solutions, sodium chloride, sodium hydrogencarbonate.
- the physiological buffer solution preferably has a pH of approx. 6.0-8.0. especially a pH of approx. 6.8-7.8. in particular a pH of approx. 7.4. and/or an osmolarity of approx. 200-400 milliosmol/liter. preferably of approx. 290-310 milliosmol/liter.
- the pH of the pharmaceutical composition is in general adjusted using a suitable organic or inorganic buffer, such as. for example, preferably using a phosphate buffer, tris buffer (tris(hydroxyl-methyl)ami-nomethane).
- a suitable organic or inorganic buffer such as. for example, preferably using a phosphate buffer, tris buffer (tris(hydroxyl-methyl)ami-nomethane).
- the cells should be formulated and stored, e.g. by freezing, in order to facilitate viability of the cells by choosing appropriate conditions as known to the skilled person.
- IGF insulin-like growth factor
- SDF-I stromal-derived factor- 1
- VEGF vascular endothelial growth factor
- HGF hepatocyte growth factor
- the present cells are injected into a site of a recipient host, and let the cell stand for a certain period of time in order to regenerate into a tissue or organ.
- the medicament of the present invention can be administered to a subject by any route suitable for the administration of viable cells. Examples of such routes are intravascularly. intracranially. intracerebral Iy. intramuscularly, intradermally. intravenously, intraocularly, intraperitoneally, orthotopically in an injured organ or by open surgical procedure.
- the pharmaceutical composition may be administered to the subject by e.g. injection, infusion or implantation.
- the medicament may be administered orthotopically. directly to the tissue or organ to be treated or reconstituted, i.e. the target tissue or target organ, or to a distant site.
- the medicament is injected into the peritoneum.
- the medicament also referred to as pharmaceutical composition
- transplantation refers to a process where a cell, a tissue or an organ is removed from a donor or otherwise prepared from non-host source such as using genetic engineering techniques and implanted into a patient or recipient.
- the recipient may receive a cell, a tissue or an organ from a living-related donor (syngenic transplantation) or the recipient per se.
- the most compatible match is usually a sibling, as their genetic make-up may closely match.
- the transplantation may be syngeneic, allogeneic or xenogeneic. When syngeneic or xenogeneic transplantation is conducted, rejection response may optionally obviated by any method known in the art such as administering immunosuppressive agent (e. g. azathiopurine. cyclophosphamide etc.).
- immunosuppressive agent e. g. azathiopurine. cyclophosphamide etc.
- the present invention is particularly suitable for allotransplatation of MAB-like cells, wherein MAB-like cells are obtained from a subject, optionally propagated, genetically modified, converted into inducible pluripotent stem cell-like cells (iPS-like cells: see below) and/or differentiated, and returned to the same subject in order to treat or prevent a disease or pathological condition. particularly a cardiovascular or ischemic disease.
- MAB-like cells are obtained from a subject, optionally propagated, genetically modified, converted into inducible pluripotent stem cell-like cells (iPS-like cells: see below) and/or differentiated, and returned to the same subject in order to treat or prevent a disease or pathological condition.
- iPS-like cells inducible pluripotent stem cell-like cells
- the MAB-like cells may be used to prepare a medicament to be administered to a subject suffering a pathological condition or a disease, particularly a cardiovascular or ischemic disease.
- a pathological condition is any abnormal condition of the body of the subject.
- the pathological condition or disease is selected from the group consisting of from cancer, an autoimmune disease, a neurodegenerative disease, a respiratory disease, a vascular disease, diabetes mellitus, Alzheimer ' s disease, Lewy body dementia.
- Parkinson ' s disease a trauma, burn, head trauma, spinal cord injury, stroke. myocardial infarction, arthrosis. Huntington's disease, Tourette's syndrome, multiple sclerosis, amyotrophic lateral sclerosis.
- Addison's disease pituitary insufficiency, liver failure, inflammatory arthropathy, neuropathic pain, blindness, hearing loss, arthritis, a bacterial infection, a viral infection, a sexually transmitted disease and a damage of the skin, the eye. the nose, the ear.
- the MAB-like cell is isolated from a subject ' s blood.
- the term "subject" can mean either a human or non-human triploblastic animal, preferably mammals, especially primates, such as humans.
- Hepatocyte growth factor/scatter factor which is a paracrine cellular growth, motility and morphogenic factor, may be used for mobilization of MAB-like cells. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells. It has been shown to have a major role in embryonic organ development, in adult organ regeneration and in wound healing. Hepatocyte growth factor regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c- Met receptor.
- HGF/SF Hepatocyte growth factor/scatter factor
- inactive polypeptide It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule.
- the protein belongs to the plasminogen subfamily of Sl peptidases but has no detectable protease activity. Alternative splicing of this gene produces multiple transcript variants encoding different isoforms. However, the inactive pro-peptide as well as the splice variants may be used in the context of the present invention.
- a HGF-elevating agent may be used in order to mediate mobilization of MAB-like cells into the subject ' s blood.
- heparin or a functionally active derivative thereof, such as a low-molecular-weight heparin (LMWH: see below).
- LMWH low-molecular-weight heparin
- Heparin is a highly-sulfated glycosaminoglycan, which is widely used as an injectable anticoagulant and has a very highest negative charge density.
- Heparin is a member of the glycosaminoglycan family of carbohydrates (which includes the closely-related molecule heparan sulfate) and consists of a variably-sulfated repeating disaccharide unit. The most common disaccharide unit is composed of a 2-O-sulfated iduronic acid and 6-O-sulfated. N-sulfated glucosamine. IdoA(2S)-GlcNS(6S).
- Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of molecular weight usually range from 3000 to over 40.000 Daltons. making up polydisperse pharmaceutical-grade heparin. Pharmaceutical grade heparin is usually derived from mucosal tissues of slaughtered meat animals such as porcine intestine or bovine lung. However, the effects of natural or unfractionated heparin can be difficult to predict. After a standard dose of unfractionated heparin, coagulation parameters should be monitored very closely to prevent over- or under-anticoagulation. Therefore, the average molecular weight of most commercial heparin preparations is in the range of 12 kDa to 15 kDa.
- the derivate may be a chemically modified heparin and/or a heparin fragment.
- the functionally active derivative, especially fragment, of heparin is characterized by having a biological activity similar to that displayed by heparin, particularly the ability to induce mobilization of MAB-like cells.
- the derivative of heparin is functionally active in the context of the present invention, if the activity of the derivative amounts to at least 10%, preferably at least 25%. more preferably at least 50%. even more preferably at least 70%, still more preferably at least 80%. especially at least 90%, particularly at least 95%. most preferably at least 99% of the activity of heparin.
- LMWHs low-molecular-weight heparins
- LMWHs low-molecular-weight heparins
- LMWHs are defined as heparin salts having an average molecular weight of less than about 8000 Da and for which at least 60% of all chains have a molecular weight less than about 8000 Da.
- a further functionally active heparin derivative is fondaparinux (Arixtra), which is a synthetic pentasaccharide, whose chemical structure is almost identical to the AT binding pentasaccharide sequence.
- fondaparinux is a synthetic pentasaccharide, whose chemical structure is almost identical to the AT binding pentasaccharide sequence.
- the identity and sequence of the five monomeric sugar units contained in fondaparinux is identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate (HS). that can be found within polymeric heparin and heparan sulfate.
- HS heparan sulfate
- One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced thrombocytopenia is substantially lower.
- agents elevating the subject ' s HGF level include Hepatocyte growth factor activator precursor (EC 3.4.21.-) (HGF activator; HGFA) including Hepatocyte growth factor activator short chain and Hepatocyte growth factor activator long chain.
- HGF or an HGF elevating agent may be done by applying the substance in question to the subject as known to the skilled practitioner. Methods of administration are detailed in the present description.
- the mesoangioblast-like cell has been or is obtained from an adult ' s blood.
- An adult in the context is of present invention relates to a subject sexual and/or physical mature.
- Sexual maturity is the age/stage when an organism can reproduce.
- Physical maturity is the age/stage at which the subject reaches its maximum height and secondary sex characteristics (e.g. for humans form such as body hair and facial hair, voice lowers in pitch, and menses begin (women)).
- HGF or an HGF-elevating agent particularly HGF. heparin or HGF activator, is envisioned, in order to increase the number of MAB-like cells in the adult ' s blood.
- the mesoangioblast-like cell has been or is obtained from a mammal.
- mammals include without limitation rat. mouse. cat. dog. horse, pig. cow. rabbit, sheep, goat and particularly primates, especially humans.
- the human subject may be a child (postnatal being before adolescence as defined above) or an adult.
- the child or adult is suffering from a cardiovascular disease requiring regenerative treatment, such as cardiac repair.
- the mesoangioblast-like cell may be characterized by the presence and/or absence of particular markers.
- the presence and absence of these markers may be determined using methods known to the skilled person such as FACS analysis. RT-PCR. immunostaining and/or cytochemical staining. The methods may be carried out e.g. as described in the Examples.
- he feature negative for a marker refers to the identification of marker on the surface of cells using e.g. FACS analysis or RT-PCR as detailed in the Examples.
- a MAB-like cell is marker negative, if the signal obtained with the respective detection method is below the threshold or not significantly different from the background or the negative control.
- a MAB-like cell is marker positive, if the signal obtained with the respective detection method is above the threshold or significantly increased relative to the background or negative control.
- the MAB cell is characterized by the presence of mesenchymal (e.g. CD73 and/or CD 13) and endothelial (e.g. KDR. CDl 05. Tie2 and/or VE-cadherin markers), but lacks the hematopoietric factor CD45.
- the mesenchymal marker may be CD73 and/or CD 13. Additionally, the following mesenchymal marker may be present: CD44. Particularly, the presence of the following combinations of these markers may be identified:
- the endothelial marker may be KDR (CD309). Tie2, CD 105 and/or VE-cadherin (CD 144). Particularly, the presence of the following combinations of these markers may be identified:
- the MAB-like cell is characterized the absence of CD45. Moreover, one or both of the following factors may be absent: CD34 and/or CDl 33. Particularly, the absence of the following combinations of these markers may be identified:
- the MAB-like cell is characterized by the presence of CD73 or KDR (VEGF-receptor-2). optionally also the presence of one or more markers selected from the group consisting of Oct3/4. Klf4. c-myc and Soxl 7: and the absence of CD45. optionally also the absence CD34 or CDl 33. or
- CD73 and KDR VEGF-receptor-2). optionally also the presence CD44. Klf4. Oct3/4 and CD29. and the absence of CD45. optionally also the absence CD34 and CDl 33. or - especially the presence of CD105. CD144. KDR. CD13, CD73. CD29 and CD44 and the absence of CD34. CD45, CD133 and CD18, or most preferably the presence of CD73. KDR (VEGF-receptor-2). Oct3/4, Klf4, c- myc and Soxl 7. and the absence of CD45. CD34 and CD133.
- the MAB-like cell may be characterized by the presence of one or more stem cell markers.
- An example of these markers includes islet- 1.
- stem cell properties of the cells may be proven by high telomerase activity.
- Suitable methods for determining the presence and absence of these factors and marker include flow cytometry, immunohistochemistry and RT-PCR and are described into more detail in the Examples.
- the mesoangioblast-like cell is defined by one or more of the following: i) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject ' s exposure to HGF and/or wherein the subject is exposed to 0.01 to 100 ⁇ g/kg bodyweight HGF: ii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject ' s exposure to heparin or a functionally active derivative thereof, e.g.
- a low-molecular- weight heparin and/or wherein the subject is exposed to 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin; or iii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject ' s exposure to a combination of (i) HGF and (ii) heparin or a functionally active derivative thereof, e.g.
- a low-molecular-weight heparin and/or wherein the subject is exposed to (i) 0.01 to 100 ⁇ g/kg bodyweight HGF and (ii) 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular- weight heparin.
- HGF or an HGF-elevating agent such as heparin or a functionally active heparin derivative
- HGF or an HGF-elevating agent may be used in order to mediate mobilization on MAB-like cells into the subject ' s blood.
- HGF or an HGF-elevating agent such as heparin or a functionally active heparin derivative
- the above regimen with respect to time and or concentration of the agent mobilizing MAB-like cells may be followed.
- the time between agent application and isolating of MAB-like cells may be further specified as 1 h to 72 h after the subject ' s exposure to the agent, particularly at least 2h to 48 h, preferably 2h to 36 h. more preferably 2h to 12 . even more preferentially 2-6 hours.
- the concentration of the agent mobilizing MAB-like cells may be further specified as
- the mesoangioblast-like cell is capable of differentiating into a mesoderm-derived cell, particularly into one. two or three cardiovascular lineage(s).
- the mesoderm is a one of the three germ layers.
- embryogenesis the zygote undergoes rapid cell divisions with no significant growth, producing a blastula.
- gastrulation cells migrate to the interior of the blastula. consequently forming three (triploblastic) germ layers.
- the embryo during this process is called a gastrula.
- the germ layers are referred to as the ectoderm, mesoderm and endoderm.
- the germ layers eventually give rise to all of an animal " s tissues and organs through the process of organogenesis.
- the mesoderm generally gives rise to the following organs or tissues bones, most of the circulatory system, including the heart and major blood vessels, connective tissues of the gut and integuments, mesenchyme, mesothelium, skeletal muscles, peritoneum (lining of the coelom), reproductive system, urinary system (including the kidneys).
- the mesoangioblast-like cell is capable of differentiating into cells of at least one of these organs or tissues. More preferably, the mesoangioblast-like cell is capable of differentiating into one. two or three cardiovascular lineage(s).
- a cardiovascular lineage describes cardiovascular cells with a common ancestry, which is developing from the same type of identifiable immature progenitor cell.
- the functional heart is comprised of distinct mesoderm-derived lineages including cardiomyocytes. endothelial cells and vascular smooth muscle cells.
- cardiovascular progenitor that represents one of the earliest stages in mesoderm specification to the cardiovascular lineages.
- the capability of MAB-like cells to differentiate into several cardiovascular lineages identify MAB-like cells as a progenitor that defines one of the earliest stages of human cardiac development. Consistently.
- MAB-like cells express the marker KDR. which defines early cardiovascular progenitor cells in embryonic stem cells (Yang et al. Nature. 2008 May 22:453(7194):524-8).
- the mesoangioblast-like cell may be differentiated into a mesoderm-derived cell, particularly a cardiovascular cell.
- a mesoderm-derived cell particularly a cardiovascular cell.
- These cells may be transplanted into the organ or tissue requiring repair or regeneration, e.g. the myocardium.
- "Differentiation” in the present context refers to a status of cells in which the cells develop specific morphological or functional properties. Cells may "differentiate” into a specific tissue or organ.
- “differentiation” refers to develop at least one property of a cell of the cardiovascular system. Typical characteristics of these cells (e.g. smooth muscle cells, endothelial cells and cardiomyocytes) are detailed herein.
- organ refers to two or more adjacent layers of tissue, which layers of tissue maintain some form of cell-cell and/or cell-matrix interaction to form a microarchitecture.
- tissue refers to a group or layer of similarly specialized cells which together perform certain special functions.
- the mesoangioblast-like cell may be used for the treatment of a cardiovascular disease and/or an ischemic disease, particularly wherein the cardiovascular and/or ischemic disease is selected from the group consisting of myocardial infarction, heart failure and peripheral vascular occlusive disease. Cardiovascular diseases as well as ischemic diseases often lead to irreversible damages of organs and tissues involved.
- 'cardiovascular disease refers to the class of diseases that involve the heart or blood vessels (arteries and veins). While the term technically refers to any disease that affects the cardiovascular system, it is usually used to refer to those related to atherosclerosis (arterial disease). These conditions have similar causes, mechanisms, and treatments.
- An ischaemic or ischemic disease is a disease characterized by reduced oxygen supply to the an organ or tissue, usually due to coronary artery disease (atherosclerosis of the coronary arteries). Its risk increases with age. smoking, hypercholesterolemia (high cholesterol levels), diabetes, hypertension (high blood pressure).
- Preferred examples include myocardial infarction, heart failure and peripheral vascular occlusive disease.
- Another aspect of the present invention relates to a method of isolating a mesoangioblast- like cell from a subject, comprising the steps of: a) optionally exposing a subject to HGF and/or an agent elevating the subject ' s HGF level; and b) isolating a mesoangioblast-like cell mobilized by step a) from the subject ' s blood.
- step a) of this method may be carried out as detailed above in the context of the MAB-like cell of the present invention.
- a blood sample may be taken from the subject. Particularly for mammals, this may be conveniently performed by taking venous blood from the subject. Venous blood may be obtained by venipuncture from a the mammal, e.g. a human donor, wherein usually only a small sample, e.g. 50 ml to 100 ml sample, of blood is adequate for the method of the present invention (see Examples). Blood is most commonly obtained from the median cubital vein, on the anterior forearm (the side within the fold of the elbow).
- This vein lies close to the surface of the skin, and there is not a large nerve supply.
- Most blood collection in the industrialized countries is done with an evacuated tube system consisting of a plastic hub, a hypodermic needle, and a vacuum tube.
- blood may also be obtained by any other method known to the skilled person.
- MAB-like cells are isolated from the blood sample. These cells may be isolated on the basis of their characteristic marker profile, as defined above in the context of any of the embodiments of the present invention. This may be done with a fluorescence-activated cell sorting (FACS).
- FACS fluorescence-activated cell sorting
- MNCs mononuclear cells
- suitable culture dishes preferably coated with e.g. fibronectin.
- suitable conditions which induce the presence of supplemental growth factors.
- suitable time e.g. after several days such as 7 days
- non-adherent cells are discarded.
- Remaining cells are MAB- like cells (and EPC after I s1 cultivation). These cells may be used or further cultivated under suitable conditions for propagation or in order to obtain differentiated cells. Additionally or alternatively, cells might be sorted by using the marker combinations described above.
- the cells may be immediately cultivated or frozen for storage as known to the person skilled in the art.
- the cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being thawed and capable of being reused.
- the cells will usually be stored in 10% DMSO. 70% autologous plasma (irradiated with 2500 rad). 20% culture medium.
- Cells may be frozen in a programmable cell freezer to -180° C in liquid nitrogen. Once thawed, the cells may be expanded by use of growth factors or cells associated with stem cell proliferation and differentiation.
- the methods of the present invention may encompass cultivation of cells under suitable conditions.
- suitable conditions include an appropriate temperature and gas mixture (typically. 37 0 C. 5% CO 2 ) in a cell incubator. Alternatively hypoxic incubators can be used.
- the most commonly varied factor in culture systems is the culture media including growth medium.
- the term "culture medium" is recognized in the art. and refers generally to any substance or preparation used for the cultivation of living cells. Recipes for growth media can vary in pH. glucose concentration, growth factors, and the presence of other nutrient components. The factors used to supplement media are often derived from animal blood, such as calf serum or by a feeder layer.
- Culture conditions may vary from species to species: however, typical conditions are the following are:
- Exemplary procedures for isolating the cells of the invention are as follows: Blood samples may be collected, e.g. from the patients who undergo open heart surgery with cardiopulmonary bypass.
- Mononuclear cells may be isolated by Ficoll density gradient centrifugation with Biocoll separating solution (Biochrom AG. Berlin. Germany). MNCs are plated in endothelial basal medium (EBM) (CellSystems. St. Katharinen, Germany), with supplements (1 ⁇ g/ml hydrocortisone. 3 ⁇ g/ml bovine brain extract. 30 ⁇ g/ml gentamicin, 50 ⁇ g/ml amphotericin B. 10 ⁇ g/ml EGF.
- EBM endothelial basal medium
- X-vivo medium + autologous serum can be used.
- Mononuclear cells may be suspended in X vivo- 15 medium (Biowhittaker) supplemented with 1 ng/mL carrier- free human recombinant VEGF (R&D), 20% human serum and potentially with 0.1 ⁇ mol/L atorvastatin from each individual patient. Cells are seeded at a density of 6.4x10 cells/mm " at fibronectin-coated dishes (Roche).
- Still another aspect of the present invention relates to a method of producing a mesoderm- derived cell, comprising the steps of: a) optionally exposing a subject to HGF and/or an agent elevating the subject ' s HGF level: b) isolating a mesoangioblast-like cell mobilized by step a) from the subject: and c) differentiating the mesoangioblast-like cell into a mesoderm-derived cell.
- Steps a) and b) of the method of the invention of producing a mesoderm-derived cell may be carried out as detailed above in connection with the method of isolating a mesoangioblast-like cell from a subject.
- the MAB-like cells are differentiated into a mesoderm-derived cell, e.g. by addition of suitable factors inducing differentiation into the desired mesoderm-derived cell.
- suitable mesoderm-derived cells include without limitation endothelial cell, a smooth muscle cell, a cardiomyocyte, an osteoblast, an pericyte, a fibroblast, and a myofibroblast.
- the mesoangioblast-like cell may be further characterized as detailed above in the context of the MAB cells of the present invention. This is particularly true for the use of heparin as HGF elevating agent, for the characterization of the subject from which the MSB-like cell is derived, for the presence and/or absence of particular markers as defined above and for the conditions for exposure to an HGF elevating agent.
- the mesoderm-derived cell is an endothelial cell, a smooth muscle cell, a cardiomyocyte or an osteoblast.
- the above method comprises expanding, particularly clonally expanding the mesoangioblast-like cell isolated in step b).
- the differentiating of step c) may be carried out by incubating the mesoangioblast-like cell in the presence of a differentiation factor or a cell producing such factors (e.g. a cardiomyocyte for differentiation into cardiac cells (see Examples)).
- a differentiation factor or a cell producing such factors e.g. a cardiomyocyte for differentiation into cardiac cells (see Examples)
- Suitable conditions for inducing differentiation into - endothelial cells include the use of Matrigel Basement Membrane Matrix (BD
- - smooth muscle cells include the presence of TGF ⁇ or FGF8.
- - cardiomyocytes include presence of neonatal cardiomyocytes.
- a further aspect of the present invention relates to the use of a mesoangioblast-like cell of the present invention for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease, wherein the mesoangioblast-like cell has been obtained from a subject ' s blood, optionally after having been exposed to hepatocyte growth factor (HGF) and/or an agent elevating the subject's HGF level.
- HGF hepatocyte growth factor
- the medicament comprising the MAB-like cells is administered to the recipient, the cells will be applied to or migrate mainly to a target tissue or organ, e.g. an tissue or organ to be repaired. In the environment of this tissue or organ, new cells forming or regenerating the organ or tissue will be generated by differentiating the cells of the MAB-like cells into the respective cells, e.g. cardiomyocytes.
- Still another aspect of the invention relates to a method of for treating a cardiovascular disease and/or an ischemic disease comprising administering to a subject an effective amount of MAB-like cells of the present invention.
- the specific therapeutically effective amount of cells for any particular subject will depend upon a variety of factors including the condition or disease the subject is suffering from, the route of administration, the age, body weight and sex of the patient, the duration of the treatment and like factors well known in the medical arts.
- the mesoangioblast-like cell may be further characterized as detailed above in the context of the MAB cells of the present invention. This is particularly true for the use of heparine as HGF elevating agent, for the characterization of the subject from which the MSB-like cell is derived, for the presence and/or absence of particular markers as defined above, for the conditions for exposure to an HGF elevating agent, for the differentiation capacity, for the differentiation status and for its use as medicament, especially for the diseases as defined above.
- a final aspect of the present invention relates to a method of converting the mesoangioblast-like cell of the present invention (as defined in any of the above embodiments) into an inducible pluripotent stem cell-like cell, wherein the level of Sox2 protein in the mesoangioblast-like cell is increased, particularly wherein the increase is mediated by: a) transfecting the mesoangioblast-like cell of the present invention with the Sox2 gene and expressing the same: b) transducing the mesoangioblast-like cell of the present invention with the Sox2 protein: and/or c) activating a promoter directing the Sox2 gene expression in the mesoangioblast-like cell of the present invention.
- the cells obtained by the above method i.e. the inducible pluripotent stem cell-like cell
- iPS cells are cells found in most, if not all. multi-cellular organisms. They are characterized by the ability to renew themselves through mitotic cell division and differentiating into a diverse range of specialized cell types. In postnatal or adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells, but also maintain the normal turnover of regenerative organs, such as blood, skin or intestinal tissues.
- Inducible pluripotent stem cells commonly abbreviated as iPS cells or iPSCs. are a type of pluripotent stem cell artificially derived from a non- pluripotent cell, typically an adult somatic cell, by inserting certain genes.
- Induced pluripotent stem cells are believed to be identical to natural pluripotent stem cells, such as embryonic stem cells, in many respects such as the expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability, but the full extent of their relation to natural pluripotent stem cells is still being assessed.
- Inducible pluripotent stem cells are in general generated by the following method: (1) Isolation and cultivation of donor cells. (2) Transfection of cells with stem cell-associated genes (e.g. colored cells may indicate the cells expressing the exogenous genes). (3) Harvest and cultivation of the cells according to ES cell culture, e.g. using mitotically inactivated feeder cells. (4) Usually, a small subset of the transfected cells becomes iPS cells and generates ES-like colonies.
- iPS-like cells may be produced by elevating the cells Sox-2 level, which may be achieved by a) transfecting the mesoangioblast-like cell of the present invention with the Sox2 gene and expressing the same: b) transducing the mesoangioblast-like cell of the present invention with the Sox2 protein: and/or c) activating a promoter directing the Sox2 gene expression in the mesoangioblast-like cell of the present invention.
- transfected cells After some time (e.g. after 3-4 weeks), small numbers of transfected cells begin to become morphologically and biochemically similar to pluripotent stem cells, and are typically isolated through morphological selection, doubling time, or through a reporter gene and antibiotic infection.
- the MAB-like cells or iPSs may be genetically modified. This may be of particular interest in order to study the function and activity of a particular gene of interest (e.g. during embryonic development) or in order to produce animals with desired properties (e.g particular productive farm animals) resulting from the presence of a transgene or absence of a particular gene.
- mesoderm-derived cells as well as iPSs may be used as medicament as detailed for the MAB-like cells of the present invention.
- iPSs may be used as medicament as detailed for the MAB-like cells of the present invention.
- ES cells Mouse embryonic stem cells
- -RT reverse transcriptase
- H 2 O H 2 O
- F Expression of markers in representative single cell-derived clones.
- G Number of single cell-derived clones expressing the respective marker.
- A-B Endothelial differentiation in vitro (A; morphology) and in vivo (B; Hematoxilin Eosin staining) using matrigel plug assays.
- C RT-PCR of FH-I and HEX in peripheral blood-derived circulating mesoagioblasts (cMAB) isolated from 2 children. MAB obtained from human aorta, human heart, and HUVEC are shown. H 2 O served as negative control.
- D RT-PCR of ⁇ -myosin heavy chain ( ⁇ -MHC) and GAPDH of cMAB. Wnt3a and dexamethasone was used to induce cardiac differentiation.
- E RT-PCR of several transcription factors of cells isolated of 5 different donor-derived cMAB is shown. Human or rat embryonic heart are used as positive control. -RT and H 2 O served as negative control.
- FIG. 3 CeIl mediated functional recovery in a hind limb ischemia (A), and myocardial infarction (MI) model (B-D) using nude mice.
- B-C Pressure-volume loop analysis using Millar catheter was performed. Representative pressure-volume curve (B) and quantification (C) are shown. * indicates p ⁇ 0.01 vs sham.
- D Human specific RT-PCR of Tie2, troponin T, and GAPDH in heart injected with cMAB or PBS.
- A RT-PCR of CD45, KDR, and CD73 in cultivated cells, which were obtained from children or adults undergoing heart surgery with cardiopulmonary bypass.
- D RT-PCR of the HGF receptor c-Met and GAPDH in children-derived cells from 5 different donors.
- E c-Met expression by FACS.
- F Colony number derived from mononuclear cells per 10 ml rat blood after 2 weeks in culture.
- G RT-PCR of rat CD45, KDR, and CD73. Cells were obtained from rats after injection of HGF.
- MNCs were plated at 8* 10 6 cells/ml on a fibronectin-coated dish in endothelial basal medium (EBM) with supplements (1 ⁇ g/ml hydrocortisone, 3-12 ⁇ g/ml bovine brain extract, 30-50 ⁇ g/ml gentamicin, 50 ⁇ g/ml amphotericin B, 10 ⁇ g/ml EGF, and 20% fetal calf serum). After 7 days in culture, non-adherent cells were discarded and cells were cultured for additional 7 days in same medium. On day 15, cells were detached by 0.25% Trypsin- EDTA (GIBCO) and were seeded at 5> ⁇ 10 4 cells/ml on fibronectin-coated dishes.
- EBM endothelial basal medium
- GEBCO Trypsin- EDTA
- X-vivo medium + autologous serum can be used.
- Mononuclear cells were suspended in X vivo- 15 medium (Biowhittaker) supplemented with 1 ng/mL carrier- free human recombinant VEGF (R&D), 0.1 ⁇ mol/L atorvastatin (provided by Pfizer), and 20% human serum drawn from each individual patient. Cells were seeded at a density of 6.4x10 5 cells/mm 2 at fibronectin-coated dishes (Roche).
- Single cell cloning For single cell cloning, cells of 2 nd -3 rd passage were labelled with CM- DiI (Invitrogen) and seeded at a single cell density on fibronectin-coated 96well plates. Single-cell deposition was confirmed microscopically and wells containing more than one cell were excluded.
- CM- DiI Invitrogen
- HAVEC Human umbilical vein endothelial cells
- endothelial basal medium supplemented with 1 ⁇ g/mL hydrocortisone, 12 ⁇ g/mL bovine brain extract, 50 ⁇ g/mL gentamicin, 50 ng/mL amphotericin-B, 10 ng/mL epidermal growth factor and 10% fetal bovine serum.
- MSCs Mesenchymal stem cells
- the CD34 + hematopoietic progenitor cells were isolated from human peripheral blood by immunomagnetic purification.
- Human mesoangioblasts were obtained from the tissue of ascending aorta from explanted heart in collaboration with Dr. G. Cossu (A. Dellavalle et al., Nat Cell Biol 9, 255-67 (2007)).
- Aortic tissue was explanted on gelatin-coated dishes and outgrowth cells were used for the experiments.
- Hind limb ischemia, cell injection and functional evaluation The in vivo angiogenic capacity was examined in a unilateral hind limb ischemia model using 8- to 10-week-old athymic ⁇ MRI nude mice (Harlan, Borchen, Germany). The proximal portion of the right femoral artery including the superficial and the deep branch and the distal portion of the saphenous artery were occluded with an electrical coagulator. Then I x IO 6 cells in 50 ⁇ l PBS were injected intramuscularly at 4 different sites. The overlying skin was closed by using surgical staples.
- ischemic (right)/nonischemic (left) limb blood flow ratio by using a laser Doppler blood flow imager (Laser Doppler Perfusion Imager System, moorLDI-Mark 2; Moor Instruments, Wilmington, DE). Data are expressed as the ratio of ischemic to nonischemic hind limb.
- Myocardial infarction was induced by permanent ligation of the left coronary artery in 10- to 12-week-old athymic ⁇ MPJ nude mice (Harlan). Soon after iigation, l *10 6 cells or PBS (both 50 ⁇ l) were injected intramuscularly into the border zone at 3 different sites. On day 14 or day 28 (Sox2 transduction), cardiac catheterization was performed for functional analysis by using 1.4F micromanometer-tipped conductance catheter (Millar Instruments Inc). Left ventricular (LV) pressure and its derivative (LV dP/dt) were continuously monitored with a multiple recording system. All data were acquired under stable hemodynamic conditions.
- Flow cytometry Following antibodies (Abs) were used for fluorescence activated cell sorting (FACS): Phycoerythrin (PE)-conjugated anti-CD13, CD14, CD31, CD34, CD44, CD45, CD73, CD146 (BD Biosciences), CD 105, CD144, KDR (R&D), CD133 (Miltenyl Biotec), Fluorescein (FITC)-conjugated anti-CD117 (Santa Cruz), biotinylated c-Met, Allophycocyanin (APC)-conjugated streptavidin, and i so type-matched PE, FITC, or APC- conjugated mouse immunoglobulins. Samples were analyzed by a flow cytometer, BD FACS Calibur cell sorter (BD Biosciences, San Jose, CA).
- FACS fluorescence activated cell sorting
- RNAs were isolated by using TRIzol (Invitrogen) or RNeasy Mini Kit (Qiagen). RNA was subjected to RT-PCR by using Superscript First Strand Synthesis System (Invitrogen). The primer sequences are available upon request. For subcloning and sequencing RT-PCR products were purified by Gel Extraction kit (Qiagen) and were subcloned by using pGEM-T Easy vector (Promega) and 6 clones were collected. Each clone was amplified and sequences were analyzed (SeqLab, Germany).
- Quantitative RT-PCR was performed on LightCycler 1.2 (Roche Diagnostics) or StepOnePlusTM Real Time PCR System (Applied Biosystems).
- Chromatin immunoprecuipitation (ChIP) Assay For each immunoprecipitation, approximately 5x10 6 cells were crosslinked with 1% formaldehyde for 5 min. at room temperature and quenched by addition of glycine (1.25M). The cell lysate was sonicated by using a Branson 450 Sonifier with 4 pulses for 5 sec. with 30% Output to sheer chromatin- DNA complex. For histone ChIPs, EZ ChIP kit (Upstate Biotechnology) was used and followed the manufacturer's protocols.
- Table 1 In vitro differentiation assay of children derived circulating mesoangioblasts- like cells for osteoblasts, smooth muscle cells (SMC), and cardiomyocytes (CM). (Stimuli, matrixes, medium, and duration of the cultivation are indicated)
- Alkaline phosphatase (ALP) expression was confirmed by StemTAGTM Alkaline Phosphatase Activity Assay Kit (Cell Biolabs Inc.) according to the manufacturer's instructions. Immunofluorescence was performed to confirm smooth muscle cells (SMC) differentiation using anti-smooth muscle actin (SMA) antibody after 14 days of culture. To induce cardiac differentiation, cells were co-cultured with neonatal cardiomyocytes (CM) for 6 days as previously described with a minor change (C. Badorff et al., Circulation 107, 1024-32 (2003); M. Koyanagi et al., J Biol Chem 280, 16838-42 (2005)).
- SMC smooth muscle cells
- SMA smooth muscle actin
- CM CM-coated cells
- Wnt3a 100 ng/ml
- dexamethasone (1OnM) were added without co-culturing rat CM.
- ⁇ MHCp-GFP cells were cotransduced with or without Sox2 and cells were cultured on gelatine coated dishes in cardiomyocytes conditioned medium. After 7 days, GFP expressions were analyzed by flow cytometry.
- Tube Formation Assay (In Vitro Matrigel Plug Assay): Cells (2x10 5 ) were cultured in a 12-well plate (Greiner) coated with 200 ⁇ L of Matrigel Basement Membrane Matrix (BD Biosciences). Tube length was quantified after 48 hours by measuring the cumulative tube length in four random microscopic fields with a computer-assisted microscope using the program KS300 3.0 (Zeiss).
- CM-DiI (Invitrogen) labeled cells (l ⁇ l O 6 ) were resuspended in 30 ⁇ l PBS and mixed with 500 ⁇ l of Matrigel Basement Membrane Matrix (BD Biosciences) containing 15 U of heparin (Sigrna- ⁇ drich).
- the cell-inairigei mixture was injected subcutaneously into 6- to 8-week-old female athymic nude mice (Harlan) along the abdominal midline.
- Matrigel plugs After 7 days, blood vessel growth in Matrigel plugs was quantified by analysis of CD31 -stained sections using microscopy. For hemoglobin analysis, the Matrigel plug was removed after 7 days and homogenized in 130 ⁇ L of deionized water. After centrifugation, the supernatant was used in the Drabkin assay (Sigma-Aldrich) to measure hemoglobin concentration. Stock solutions of hemoglobin are used to generate a standard curve. Results are expressed relative to total protein.
- mice and Matrigelplugs were fixed with 10% buffered formalin and embedded in paraffin, processed for light microscopy, and stained with hematoxylin and eosin.
- mice and Matrigelplugs were embedded in optimal cutting temperature compound (O. C. T. compound), and were quickly frozen in liquid nitrogen and cut in 5 ⁇ m sections.
- Immunostaining For immunohistochemistry of cultured cells, cells were fixed with 4% paraformaldehyde. After permeabilization with 0.2% saponin (Sigma), cells were incubated with the respective antibodies (CD31 ; Chemicon, smooth muscle actin; Sigma, alpha sarcomeric actinin; Sigma, GATA4; Santa Cruz, Nkx2.5; Santa Cruz, Oct3/4; Cell Signaling, IsI-I; R&D, nanog; Abeam, Sox2; Abeam, nestin; Abeam, Cytokeratin 18 (CKl 8); Chemicon).
- the specimens from frozen tissue sections were fixed with 4% paraformaldehyde, followed by staining with the respective antibodies (human nuclear antigen; Chemicon, smooth muscle actin; Sigma, alpha sarcomeric actinin; Sigma). Nuclei were counterstained with To-pro-3 iodide, Sytox Blue (both Molecular Probes) or DAPI according to the manufacturer's instructions. The images were recorded by confocal microscope (LSM510-META, Carl Zeiss, Oberkochen, Germany).
- cMABs and MSC were lysed with lysis buffer (Cell Signaling) containing ImM phenylmethanesulfonyl fluoride. After centrifugation the supernatants were collected and subjected to electrophoresis in 10% SDS-polyacrylamide gels. Proteins were transferred to poly vinylidene difluorid membrane, and incubated with anti-Tie2 (BD), anti-nanog (Abeam), anti-Oct3/4 (Oct4A, Cell Signaling), anti-Klf4 (Abeam), anti- myc (Santa Cruz), anti-Sox2 (Abeam), or anti-beta actin (Sigma) overnight at 4 0 C. Bound antibodies were visualized by using horseradish peroxidase (HRP)- conjugated sheep anti- mouse or donkey anti-rabbit antibody (both Amersham).
- HRP horseradish peroxidase
- Fluorescence in situ hybridization For fluorescence in situ hybridization 6 ⁇ m sections were prepared from formalin-fixed, paraffin-embedded tissue blocks according to standard procedures. After deparaffinization sections were submitted to heat-induced epitope retrieval by boiling for 22 minutes in 1 mmol/L sodium citrate buffer (pH 8.0). Sections were fixed with 1% paraformaldehyde/PBS on ice for 10 minutes. The human AIu probes were used for fluorescence in situ hybridization (FISH) (C. Bearzi et al., Proc Natl Acad Sci U S A 104, 14068-73 (2007)). Probes were dehybridi sized for 4 min. at 71°C before incubation of probes with samples (4 min.
- FISH fluorescence in situ hybridization
- Cytokine Array Patient's serum was analyzed by using a cytokine antibody array from RayBio Human Cytokine Antibody Array (RayBiotech, Inc, Norcross, Ga) according to the manufacturer's instructions. A semiquantitative analysis of the comparative intensity of the spots was performed with an image analysis program (TINA; version 2.09g).
- Islet- 1 for AGTGTAATCAGTATTTGGACGAGAG 29
- lentiviral vectors containing the enhanced green fluorescent protein (GFP) gene, alpha myosin heavy chain (MHC) promoter (accession number: U71441) GFP, eNOS promoter (accession number: AF387340) GFP, or the human SOX2 gene and a WPRE (woodchuck posttranscriptional regulatory element) under the control of a spleen focus-forming virus promoter were generated by transient transfection of 293T cells using pCMV ⁇ R8.91 as packaging plasmid and pMD2.G for vesicular stomatitis virus-G protein (VSV-G) pseudotyping. After 8 hours, the medium was replaced by EBM supplemented with EGM SingleQuots and 20% FBS. The supernatant was collected every 24 hours for 2 days, pooled (200 to 250 mL), and filtered through 0.22- ⁇ m filters.
- GFP green fluorescent protein
- MHC alpha myosin heavy chain
- Lentiviral Transduction For lentiviral transduction, isolated cells were transduced at 2nd - 3rd passages. Transduction was carried out by adding viral supernatant to the EBM supplemented with EGM SingleQuots and 20% FBS. After 6 hours, medium was changed and the cells were transduced a second time.
- Echocardiography In order to control initial infarct size and check the left ventricular function, we performed echocardiography analysis (Visualsonics; Vevo770). Initial infarct size was evaluated by left ventricular diastolic dimension (LVDd) and wall motion score index (Zhang et al., 2007, Am J Physiol Heart Circ Physiol 292, Hl 187-1192) soon after coronary ligation. Echocariography was performed by a blinded single observer. Statistics: Data are expressed as mean +_SEM. Unpaired two-tailed student's t-test, Mann- Whitney U-test (to compare 2 groups) or ANOVA (> 3 groups) were used for the comparison between groups based on the original data. Single regression analysis was performed to investigate the relation of donor age and population doubling.
- Circulating progenitor cells contribute to neovascularization and have been used for cell therapy of ischemia.
- Endothelial progenitor cells isolated from adult blood are characterized by coexpression of hematopoietic and endothelial markers, analogue to the hemangioblast.
- vessel-associated multipotent progenitors the so called mesoangioblasts (MAB) have been experimentally described.
- MAB express the key marker of angiopoietic progenitors, KDR, as well as mesenchymal markers.
- EXAMPLE 2 Circulating mesoangioblasts differentiate into cardiac myocytes and improve function after acute myocardial infarction
- Example 1 The cells described in Example 1 were tested for their potential of cardiac differentiation For this, we tested the capacity of children-derived MAB to acquire a cardiomyogenic phenotype.
- MAB expressed several cardiac transcription factors such as Nkx2.5, GAT A4 and MEF2C and the stem cell marker islet- 1 (figure 2e).
- CM neonatal rat cardiomyocytes
- TnT human troponin T
- Sequences of the cloned RT-PCR products were identical to human TnT except for the known mutation providing genetic proof of concept for cardiac differentiation.
- human TnT also was detected, indicating that differentiation is sufficient to induce cardiac markers gene expression.
- MAB was injected intramuscularly in nude mice after myocardial infarction.
- children-derived MAB express cardiac-specific genes after co-culture with CM and improved cardiac function in vivo. Given that MAB can be easily isolated and expanded from peripheral blood, these cells might be suitable to augment cardiac repair in children with heart failure.
- EPC Endothelial progenitor cells
- Notch families of proteins are transmembrane receptors. After binding with their ligands, Notch intracellular domain (NICD) is cleaved and contributes to cardiovascular development. Notch activation was transiently detected in EPC as determined by immunhistochemical detection of the NICD and expression of human Notch target genes. Inhibition of ⁇ -secretase blocked Notch cleavage and NICD translocation. Furthermore, the expression of the cardiac marker proteins were significantly suppressed by ⁇ -secretase inhibition indicating that Notch activation facilitates cardiac marker gene expression.
- Wnt5a expression was induced in the human cells by the co-culture and was blocked by ⁇ -secretase inhibitor.
- Notch and Wnts signaling contributed to cardiac differentiation of EPC.
- Wnt5a pretreated EPC can differentiate to CM in vivo after myocardial infarction, suggesting this enhancing strategy might be suitable for cardiac repair.
- EPC EPC progenitor cells
- progenitor cells circulating progenitor cells isolated from children and from adults, and found that progenitor cells from children have a greater proliferative capacity which was significantly correlated with age.
- the marker profiles of the clonally expanded cells is distinct from adult circulating "endothelial" progenitor cells (EPC), but resemble but are not identical as mesoangioblasts and unrestricted somatic stem cells (USSCs).
- novel progenitor cells isolated from children have a greater proliferative and greater cardiomyocyte differentiation capacity than EPC, and improve cardiac function after myocardial infarction. Therefore, these cells may be an alternative for the heart failure treatment.
- EXAMPLE 4 Identification of a novel subset of multipotent circulating stem cells with a high capacity for cardiovascular regeneration
- Example 1 we identified circulating MAB-like cells in children.
- Children-derived MAB like cells cMABs
- cMABs showed vigorous proliferation capacity and high telomerase activity.
- cMABs showed several stem cell features, the potential for cardiovascular repair and regeneration is not known.
- EC differentiation was determined by using matrigel assays (figure 2a/b). Tube like-structures were formed in vitro and in implanted matrigel plugs in vivo to a similar extent as compared to human umbilical cord endothelial cells (HUVEC). cMABs expressed endothelial markers and connected to the mouse vasculature leading to increased perfusion of the plugs (+133% increase).
- cMABs After 6 days of co-culture, cMABs acquired a CM fate as demonstrated by the expression of ⁇ -sarcomeric actinin by immunohistocemistry (IHC) and by the expression of human troponin T (TnT) mRNA. Even in the absence of co-culture, incubation with Wnt3a, which was previously shown to promote CM differentiation of embryonic stem cells, increased the expression of Nkx 2.5, ⁇ -myosin heavy chain, and TnT. In line with these results, cells expressed various muscle transcription factors such as GATA-4, Mef-2C, while only some clones expressed Nkx2.5. Interestingly, cMABs strongly expressed Islet- 1, which was previously shown to make a multipotent primordial cardiovascular progenitors. Taken together, cMABs are multipotent and can differentiate into the 3 distinct cardiovascular cell lineages.
- IHC immunohistocemistry
- TnT human troponin T
- mice were injected in a nude mice model of hind limb ischemia. After 14 days, the recovery of blood flow was significantly greater in mice treated with cMABs compared to PBS-treated control mice. In addition, cMABs were injected in mice after induction of myocardial infarction. After 2 weeks, cell-treated mice exhibited a smaller infarct size and a significantly improved cardiac function with lower left ventricular end- diastolic pressures, and improved diastolic function (Tau) (LVEDP: -56.0%, Tau: -20.3%).
- cMABs differentiated to all three cardiovascular lineages in vitro and in vivo. Moreover, cMABs improved neovascularization and cardiac function after ischemia.
- these circulating cMABs can be easily isolated and expanded from peripheral blood, these cells might be suitable to augment cardiac repair in children with heart failure.
- EXAMPLE 5 Detailed characterization of circulating mobilizable multipotent mesoangioblasts in humans
- Blood-derived circulating mononuclear cells were obtained from children undergoing cardiopulmonary bypass for cardiac surgery. Cells were cultivated on fibronectin-coated dishes and first clones were detected after 1-2 weeks. Overall, 1.1 to 2.1 colonies were detected per ml blood after 2 weeks of culture. Cells showed a spindle-shaped morphology, exhibited a high proliferative capacity, and were cultured for 28.3+0.9 passages (Fig. IA). The proliferative capacity was closely correlated with the donor age (Fig. 1A/B) and was associated with a high telomerase activity, which was detected at least until the 15 th passage (Fig. 1C).
- KDR and Tie2 clearly distinguishes the isolated cells from mesenchymal stem cells (Table 2). Moreover, although the cells are CD105 + KDR + , the absence of CD31 and lack of the hematopoietic markers CD34 and CD45 distinguish the cultivated children-derived cells from circulating endothelial and hematopoietic progenitor cells (Table 2 and (Ingram et al., Blood 104, 2752-60 (2004), Lin et al, J Clin Invest 105, 71-7 (2000), Timmermans et al., Arterioscler Thromb Vase Biol 27, 1572-9 (2007)).
- mesoangioblasts which are multipotent progenitors of mesodermal tissue originally isolated from the embryonic dorsal aorta and characterised by the expression of mesenchymal and endothelial markers (Cossu and Bianco, Curr Opin Genet Dev 13, 537-42 (2003)). Consistent with the phenotype of mesoangioblasts isolated from adult tissue (Dellavalle et al., Nat Cell Biol 9, 255-67 (2007)), children-derived cells express the proteoglycan NG2, a marker for pericyte-derived cells.
- chromatin immunoprecipitation demonstrated that histone modifications associated with active transcription (histone H3 acetylation and H3 lysine 4 trimethylation) were present at the Oct3/4 and Klf4 promotor region, while heterochromatin modifications (trimethylated H3 lysine 9 and trimethylated H3 lysine 27) were low or absent .
- the repressive histone modifications trimethyl-H3 lysine 27 was high at the Sox2 promotor (Fig. IG).
- the stem cell marker Nanog (Chambers et al., Cell 113, 643-55 (2003), K. Mitsui et al., Cell 113, 631-42 (2003)) was not detected (Fig.
- the transcription factors Hex and FIi-I known to play a key role in vascular development (Guo et al., Blood 102, 2428-35 (2003), Hart et al., Immunity 13, 167-77 (2000)), were highly expressed (Fig. 2C).
- Differentiation into smooth muscle cells was achieved in individual cells by addition of TGF ⁇ l, while cultivation of the cells on jagged-coated dishes in combination with FGF8 induced the expression of smooth muscle- specific proteins in > 60 % of all cells.
- the mRNA expression of the muscle marker smooth muscle actin was additionally documented.
- Skeletal muscle differentiation was tested by co-culturing human mesoangioblasts with C2C12 mouse myogenic cells and scoring the % of human nuclei fused into myotubes. More than 10% of human nuclei fused with mouse myoblasts indicating a significant myogenic potency, even though, as in embryonic mouse mesoangioblasts, spontaneous myogenesis did not occur (Minasi et al. 2002, supra).
- cells were co- cultured with neonatal rat cardiomyocytes (Laugwitz et al., Nature 433, 647-53 (2005), Badorff et al., Circulation 107, 1024-32 (2003)).
- the blood-derived mesoangioblast-like cells are multipotent and can be directed to differentiate into the 3 distinct cardiovascular cell lineages.
- mice In order to determine the potential functional benefit using these multipotent circulating blood-derived cells for therapeutic applications, human cells were injected in a nude mice model of hind limb ischemia. After 14 days, the recovery of blood flow was significantly greater in mice treated with children-derived cells compared to PBS-treated control mice (Fig. 3A). In addition, cells were injected in mice after induction of myocardial infarction (Table 3).
- Table 3 Characteristics and cardiac functional analysis of nude mice 2 weeks after myocardial infarction (MI) treated with PBS or MAB compared to sham controls
- HR heart rate, bpm; beat per minute, LVESP; left ventricle end-systolic pressure, LVEDP; left ventricle end- diastohc pressure * indicates p ⁇ 0.01 vs sham. # and ## indicates p ⁇ 0.05 and p ⁇ 0.01 vs MI PBS group, respectively.
- cell-treated mice After 2 weeks, cell-treated mice exhibited a smaller infarct size and a significantly improved cardiac function with lower left ventricular end-diastolic pressures and improved diastolic function (Tau) (Fig. 3B/C).
- cells were injected intramyocardially in mice after induction of myocardial infarction.
- cell-treated mice exhibited a significantly, but modestly improved cardiac function with lower left ventricular end- diastolic pressures (46.2+11.0 % reduction) and improved diastolic function (Tau) (18.2+5.4 % reduction).
- the in vivo differentiation of the injected cells was assessed by immunostaining and RT-PCR.
- HGF hepatocyte growth factor
- Sox2 transduction may enhance the multipotency of the cells. Therefore, we overexpressed Sox2 by lentiviral vectors and confirmed Sox2 expression by RT-PCR, qPCR and on protein level. Sox2-transduced cMAB demonstrated a re-expression of the pluripotency associated gene Nanog and an increase in Oct3/4, although the expression was still much lower compared to embryonic stem cells.
- Sox2-transduced cMABs In order to evaluate the potential of Sox2-transduced cMABs to generate progeny of the three germ layers, we induced differentiaton in hepatocytes, neuronal cells in vitro according to published protocols (Lee et al., 2004 Hepatology 40, 1275-1284; Minasi et al., 2002, Development 129, 2773-2783; Romero-Ramos et al., 2002, J Neurosci Res 69, 894-907). Sox2-transduced cMABs efficiently differentiate to CKl 8 and ⁇ - fetoprotein expressing hepatocytes, and nestin- positive neuronal cells.
- Endothelial and cardiac differentiation was further quantified by using reporter gene assays, in which GFP is expressed under the control of the endothelial nitric oxide (eNOS) and ⁇ -myosine heavy chain (MHC) promoter, respectively.
- eNOS endothelial nitric oxide
- MHC ⁇ -myosine heavy chain
- Sox2- transduced cMABs expressed eNOS-promoter driven GFP and formed vascular networks in vitro.
- Sox2-transduced cMABs showed a rapid and more efficient induction of ⁇ MHC-promoter driven GFP expression after co-culture with rat neonatal cardiomyocytes.
- Sox2-transduced cMABs but not unmodified cMABs express MHC-promoter driven GFP when exposed to conditioned medium to induce cardiac differentiation.
- Sox2-transduced cells have the potency to differentiate into all three germ layers in vitro, at variance with untransduced cells whose potency is more restricted to solid mesoderm.
- Sox2-overexpressing cells resulted in increased numbers of ⁇ - sarcomeric actinin, smooth muscle actin, and von Willebrand factor-positive human cells compared to the injection of GFP-transduced control cMAB as shown by immunostaining and quantitative PCR.
- Sox2-transduced cMABs expressing GFP under the control of the ⁇ MHC promoter.
- GFP- expressing ⁇ -sarcomeric actinin positive cells were detected in the border zone of the infarcts.
- our studies identify a novel subset of circulating human progenitor cells, which fulfils all criteria for a cell population to be used for cardiovascular regenerative therapeutic purposes: they are easily accessible in the peripheral blood, can be expanded in vitro to large numbers, are capable to differentiate into all three distinct cardiovascular cell lineages in vitro and in vivo, secrete pro-angiogenic and cardioprotective factors, and mediate significant functional improvements after therapeutic administration in models of ischemia and infarction, specifically when transduced with Sox2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell.
Description
Mesoangioblast-like cell as well as methods and uses relating thereto
The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject's blood, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell.
The use of stem cells has been hailed as the next major step in the battle against serious degenerative disorders, such as diabetes and cardiovascular diseases, and for some debilitating or lethal neurological diseases, such as Parkinson's and motor neuron disease. Medical researchers believe that stem cell therapy has the potential to dramatically change the treatment of human disease. The two broad types of mammalian stem cells are: embryonic stem cells that are found in blastocysts, and adult (or somatic) stem cells that are found in postnatal tissues. Although the number of human embryonic stem cell lines has increased considerably in the past years, few of these have been wεϋ characterized, and large hurdles still need to be overcome to ensure safety and efficacy. These will require substantial further investment and research. However, there exists a widespread controversy over human embryonic stem cell research that emanates from the techniques used in the creation and usage of stem cells. Human embryonic stem cell research is controversial because, with the present state of technology, starting a stem cell line requires the destruction of a human embryo and/or therapeutic cloning.
It is not the entire field of stem cell research, but the specific field of human embryonic stem cell research that is at the centre of an ethical debate. In contrast to embryonic stem cells, the use of adult (postnatal) or somatic stem cells is widely accepted from an ethnical point of view. A number of adult stem cell therapies already exist, particularly bone
marrow transplants that are used to treat leukemia. In the future, medical researchers anticipate being able to use technologies derived from stem cell research to treat a wider variety of diseases including without limitation cancer. Parkinson's disease, spinal cord injuries, cardiovascular diseases and muscle damage, amongst a number of other impairments and conditions.
Also for cardiovascular regenerative medicine stem cell therapy offers novel treatment options. Several types of adult stem cells including different subsets of bone marrow- derived and tissue-resident progenitor cells were shown to induce vasculogenesis and cardiomyogenesis (Beltrami et al.. Cell 1 14. 763-76 (2003). Orlic et al., Nature 410, 701-5 (2001)). However, the number, the proliferative capacity, and the angiogenic and cardiomyogenic potential of these progenitor cells are severely limited particularly in patients with cardiovascular diseases (Vasa et al., Circ Res 89, E 1-7 (2001)).
Accordingly, there is a demand for an alternative source for adult stem cells. Preferably, these stem cells are to be isolated in a convenient, safe and economic manner. Additionally, it is preferred that these cells can be isolated from diseased patients, e.g. patients with cardiovascular diseases, particularly for allotransplantation.
Surprisingly, our studies identify a novel subset of circulating progenitor cells, which fulfill all criteria for an ideal cell population to be used, e.g. for cardiovascular regenerative therapeutic purposes: they are easily accessible in the peripheral blood, can be expanded in vitro and are capable of differentiating into distinct cell lineages in vitro and in vivo to large numbers. Additionally, hepatocyte growth factor (HGF) has been shown to mediate elevation of the level of these cells in the subject's blood. The identified cells resemble mesoangioblasts (MABs) and were therefore referred to as mesoangioblast-like cells (MAB-like cells). These MAB-like cells can be isolated from peripheral blood of children and adults.
Accordingly, a first aspect of the invention relates to a mesoangioblast-like cell, obtained from a subject's blood, as a medicament. In a particular embodiment of the present invention the subject is or has been exposed to hepatocyte growth factor (HGF) or an agent
elevating the subject's HGF level, in order to increase the number of MAB-like cells in the subject's blood.
The marker profile of the novel cells is distinct from hematopoietic or mesenchymal stem cells, but resembles embryonic multipotent mesoangioblasts (MABs). Therefore, these cells have been designated with mesoangioblast-like cells (MAB-like cells). Mesoangioblasts (MAB) are vessel-associated cells identified during embryonic development. In contrast to hemangioblasts, MABs express mesenchymal (CD73) and endothelial markers, but lack the hematopoietic marker CD45. An MAB cell of the present invention is characterized by the presence of mesenchymal (e.g. CD73 and/or CD13) and endothelial (e.g. KDR. Tie2. CDl 05 and/or VE-cadherin) markers, but lacks the hematopoietric factor CD45. Preferably. MAB-like cells are characterized by the absence of CD45 and the presence of CD73 and KDR. Additionally, the cells express one or more stem cell markers (e.g. islet- 1) and are characterized by marked proliferative capacity and high telomerase activity at least at the beginning of their cultivation (e.g. until passage 30, 25, 20. 15, 10. especially until passage 15 or 10). Most preferably. MABs are characterized by the following marker profile:
- Surface markers: expression of KDR and CD73 and absence of CD45 (and optionally absence of CD34 and CD 133): and - Transcription factors: presence of Oct3/4, Klf4, c-myc and Soxl 7. or
- Surface markers: expression of KDR. Tie2 and CD73 and absence of CD45 (and optionally absence of CD34 and CDl 33); and
- Transcription factors: presence of Oct3/4, Klf4. c-myc and Soxl 7.
By "'high proliferative activity" is meant a population doubling within at most 50 hr. preferably at most 40 hr. most preferably at most 35 hrs. MAB-like cells are multipotent and improve functional recovery after ischemia.
Additionally, examined cells were shown to be capable of differentiating into distinct cell lineages, particularly distinct cardiovascular cell lineages, especially all 3 distinct cardiovascular cell lineages in vitro and in vivo. Furthermore, they may secrete pro-
angiogenic and cardioprotective factors, and mediate functional improvements after therapeutic administration in models of ischemia and infarction. Phenotypically. these blood-derived cells may represent a correlate of embryonic dorsal aorta-derived mesoangioblasts present after birth and in the adult. Preliminary studies in children with previous gender-mismatched bone marrow-transplantation suggest that these circulating mesoangioblast-like cells are non-bone marrow-derived. Exposure of patients to cardiopulmonary bypass and cardioplegia during cardiac surgery is associated with mobilization of these mesoangioblast-like cells into the peripheral blood. The identification of HGF as a cytokine mediating mobilization of mesoangioblast-like cells into the peripheral blood not only offers the possibility to increase the number of circulating mesoangioblast-like cells, but opens up an avenue to generate patient-specific multipotent cells for therapeutic application in patients with cardiovascular disease.
Inventors identified circulating MAB-like cells in children. Children-derived MAB-like cells showed vigorous proliferation capacity and high telomerase activity. The capacity of children-derived MAB-like cells to acquire a cardiomyogenic phenotype has also been tested and confirmed. It is also shown that children-derived MAB-like cells express cardiac-specific genes after co-culture with cardiomyocytes and improved cardiac function in vivo. Since MAB-like cells can be easily isolated and expanded from peripheral blood, these cells are suitable to augment cardiac repair, e.g. in children with heart failure.
However, MAB-like cells may be also isolated from adults. The number and proliferative capacity of the cells is correlated with the donor age. but unexpectedly increased in patients undergoing extracorporal circulation. Hepatocyte growth factor (HGF), which is significantly elevated during extracorporal circulation, induces mobilization of mesoangioblast-like cells. Thus, HGF-mobilized clonally expandable, multipotent progenitor cells constitute a clinically useful source to generate subject- or patient-specific multipotent cells e.g. for therapeutic application in cardiovascular diseases.
Accordingly, the MAB-like cells may be used as a medicament, which may optionally encompass excipients and/or auxiliaries. It should be noted that a sufficient amount of
MAB-like cells should be present in the medicament. It is also possible to combine the cells of two or more subjects into one medicament.
In a preferred embodiment the number of MAB-like cells to be administered to a subject amounts to at least 10 Mio. more preferable at least 20 Mio. still more preferably at least 50 Mio MAB-like cells per treatment. It might be necessary to administer the MAB-like cells in several doses, e.g. on different days for successful treatment.
In another preferred embodiment the cells are propagated before administration. For this. the MAB-like cells are preferably disaggregated into single clones which may be further expanded in e.g. liquid cultures containing suitable media, e.g. endothelial basal medium (EBM), X vivo 10 or X vivo 15 (e.g. from Biowhittaker). with supplements (e.g. hydrocortisone, bovine brain extract, antibiotics, growth factor(s) such as epidermal growth factor (EGF) or vascular endothelial growth factor (VEGF) and/or serum such as fetal calf serum, human serum or autologous serum). This is particularly useful, if larger amount of cells are needed for therapy or prophylaxis.
For administration the MAB-like cells should be in a pharmaceutical dosage form in general consisting of a mixture of ingredients known to a skilled person in the pharmacotechnical arts such as pharmaceutically acceptable excipients and/or auxiliaries combined to provide desirable characteristics. Examples of such substances are isotonic saline. Ringer's solution, buffers, medium (e.g. EBM. X vivo 10 and X vivo 15) organic or inorganic acids and bases as well as their salts and buffer solutions, sodium chloride, sodium hydrogencarbonate. sodium citrate or dicalcium phosphate, glycols, such a propylene glycol, sugars such as glucose, sucrose and lactose, starches such as corn starch and potato starch, albumins, organic solvents, complexing agents such as citrates and urea, stabilizers, such as protease or nuclease inhibitors, The physiological buffer solution preferably has a pH of approx. 6.0-8.0. especially a pH of approx. 6.8-7.8. in particular a pH of approx. 7.4. and/or an osmolarity of approx. 200-400 milliosmol/liter. preferably of approx. 290-310 milliosmol/liter. The pH of the pharmaceutical composition is in general adjusted using a suitable organic or inorganic buffer, such as. for example, preferably using a phosphate buffer, tris buffer (tris(hydroxyl-methyl)ami-nomethane). In general, the cells
should be formulated and stored, e.g. by freezing, in order to facilitate viability of the cells by choosing appropriate conditions as known to the skilled person.
In addition to the capacity of the injected cells to contribute to tissue regeneration in its pure sense by virtue of their differentiation to the cardiovascular cell lineages, cells usually express and secrete a variety of pro-angiogenic cytokines and cardioprotective factors known to contribute to improved infarct healing. ELISA of insulin-like growth factor (IGF). stromal-derived factor- 1 (SDF-I). vascular endothelial growth factor (VEGF). and hepatocyte growth factor (HGF) was significantly higher in cMAB supernatant.
Regeneration methods are well known in the art, and those skilled in the art are able to select an appropriate method for a desired purpose without undue experimentation. In an exemplified embodiment, the present cells are injected into a site of a recipient host, and let the cell stand for a certain period of time in order to regenerate into a tissue or organ. The medicament of the present invention can be administered to a subject by any route suitable for the administration of viable cells. Examples of such routes are intravascularly. intracranially. intracerebral Iy. intramuscularly, intradermally. intravenously, intraocularly, intraperitoneally, orthotopically in an injured organ or by open surgical procedure. The pharmaceutical composition may be administered to the subject by e.g. injection, infusion or implantation. It may be administered orthotopically. directly to the tissue or organ to be treated or reconstituted, i.e. the target tissue or target organ, or to a distant site. In one embodiment of the invention the medicament is injected into the peritoneum. Most preferably, the medicament (also referred to as pharmaceutical composition) is administered intravenously, intraperitoneally or orthotopically in an organ or tissue requiring repair or regeneration.
The term "transplantation" refers to a process where a cell, a tissue or an organ is removed from a donor or otherwise prepared from non-host source such as using genetic engineering techniques and implanted into a patient or recipient. The recipient may receive a cell, a tissue or an organ from a living-related donor (syngenic transplantation) or the recipient per se. The most compatible match is usually a sibling, as their genetic make-up may closely match. The transplantation may be syngeneic, allogeneic or xenogeneic. When
syngeneic or xenogeneic transplantation is conducted, rejection response may optionally obviated by any method known in the art such as administering immunosuppressive agent (e. g. azathiopurine. cyclophosphamide etc.).
Accordingly, allotransplantation of cells is preferred. The present invention is particularly suitable for allotransplatation of MAB-like cells, wherein MAB-like cells are obtained from a subject, optionally propagated, genetically modified, converted into inducible pluripotent stem cell-like cells (iPS-like cells: see below) and/or differentiated, and returned to the same subject in order to treat or prevent a disease or pathological condition. particularly a cardiovascular or ischemic disease.
The MAB-like cells may be used to prepare a medicament to be administered to a subject suffering a pathological condition or a disease, particularly a cardiovascular or ischemic disease. A pathological condition is any abnormal condition of the body of the subject.
In a preferred embodiment the pathological condition or disease is selected from the group consisting of from cancer, an autoimmune disease, a neurodegenerative disease, a respiratory disease, a vascular disease, diabetes mellitus, Alzheimer's disease, Lewy body dementia. Parkinson's disease, a trauma, burn, head trauma, spinal cord injury, stroke. myocardial infarction, arthrosis. Huntington's disease, Tourette's syndrome, multiple sclerosis, amyotrophic lateral sclerosis. Addison's disease, pituitary insufficiency, liver failure, inflammatory arthropathy, neuropathic pain, blindness, hearing loss, arthritis, a bacterial infection, a viral infection, a sexually transmitted disease and a damage of the skin, the eye. the nose, the ear. the brain, the spinal cord a nerve, the trachea, the lungs, the mouth, the esophagus, the stomach, the liver, the small intestines, the large intestines, the kidney, the ureter, the bladder, the urethra, a gland such as hypothalamus, pituitary, thyroid, pancreas and adrenal glands, the ovary, the oviduct, the uterus, the vagina, a mammary gland, the testes, the penis, a lymph nodes, a vessel, the heart, a blood vessel, a skeletal muscle, a smooth muscle, a bone, cartilage, a tendon or a ligament.
The MAB-like cell is isolated from a subject's blood. As used herein the term "subject" can mean either a human or non-human triploblastic animal, preferably mammals, especially primates, such as humans.
Hepatocyte growth factor/scatter factor (HGF/SF), which is a paracrine cellular growth, motility and morphogenic factor, may be used for mobilization of MAB-like cells. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells. It has been shown to have a major role in embryonic organ development, in adult organ regeneration and in wound healing. Hepatocyte growth factor regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c- Met receptor. It is secreted as a single inactive polypeptide and is cleaved by serine proteases into a 69-kDa alpha-chain and 34-kDa beta-chain. A disulfide bond between the alpha and beta chains produces the active, heterodimeric molecule. The protein belongs to the plasminogen subfamily of Sl peptidases but has no detectable protease activity. Alternative splicing of this gene produces multiple transcript variants encoding different isoforms. However, the inactive pro-peptide as well as the splice variants may be used in the context of the present invention.
Alternatively, a HGF-elevating agent may be used in order to mediate mobilization of MAB-like cells into the subject's blood.
One example of an agent elevating the subject's HGF blood level is heparin or a functionally active derivative thereof, such as a low-molecular-weight heparin (LMWH: see below).
Heparin is a highly-sulfated glycosaminoglycan, which is widely used as an injectable anticoagulant and has a very highest negative charge density. Heparin is a member of the glycosaminoglycan family of carbohydrates (which includes the closely-related molecule heparan sulfate) and consists of a variably-sulfated repeating disaccharide unit. The most common disaccharide unit is composed of a 2-O-sulfated iduronic acid and 6-O-sulfated. N-sulfated glucosamine. IdoA(2S)-GlcNS(6S). Under physiological conditions, the ester
and amide sulfate groups are deprotonated and attract positively-charged counterions to form a heparin salt. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of molecular weight usually range from 3000 to over 40.000 Daltons. making up polydisperse pharmaceutical-grade heparin. Pharmaceutical grade heparin is usually derived from mucosal tissues of slaughtered meat animals such as porcine intestine or bovine lung. However, the effects of natural or unfractionated heparin can be difficult to predict. After a standard dose of unfractionated heparin, coagulation parameters should be monitored very closely to prevent over- or under-anticoagulation. Therefore, the average molecular weight of most commercial heparin preparations is in the range of 12 kDa to 15 kDa.
One alternative is a functionally active derivative, especially fragment, of heparin. The derivate may be a chemically modified heparin and/or a heparin fragment. The functionally active derivative, especially fragment, of heparin is characterized by having a biological activity similar to that displayed by heparin, particularly the ability to induce mobilization of MAB-like cells. Particularly, the derivative of heparin is functionally active in the context of the present invention, if the activity of the derivative amounts to at least 10%, preferably at least 25%. more preferably at least 50%. even more preferably at least 70%, still more preferably at least 80%. especially at least 90%, particularly at least 95%. most preferably at least 99% of the activity of heparin.
The above disadvantage of natural or unfractionated heparin led to the development of heparin derivates. particularly low-molecular-weight heparins (LMWHs). which, in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than about 8000 Da and for which at least 60% of all chains have a molecular weight less than about 8000 Da. These are obtained by various methods of fractionation or depolymerisation of polymeric heparin. Various methods of heparin depolymerisation are used in the manufacture of low-molecular- weight heparin. Examples and resulting products, which can be used in the context of the present invention, are listed below:
- Oxidative depolymerisation with hydrogen peroxide. Used in the manufacture of ardeparin (Normiflo)
- Deaminative cleavage with isoamyl nitrite. Used in the manufacture of certoparin (Sandoparin)
- Alkaline beta-eliminative cleavage of the benzyl ester of heparin. Used in the manufacture of enoxaparin (Lovenox and Clexane) - Oxidative depolymerisation with Cu2+ and hydrogen peroxide. Used in the manufacture of parnaparin (Fluxum)
- Beta-eliminative cleavage by the heparinase enzyme. Used in the manufacture of tinzaparin (Innohep and Logiparin)
- Deaminative cleavage with nitrous acid. Used in the manufacture of dalteparin (Fragmin), reviparin (Clivarin) and nadroparin (Fraxiparin)
A further functionally active heparin derivative is fondaparinux (Arixtra), which is a synthetic pentasaccharide, whose chemical structure is almost identical to the AT binding pentasaccharide sequence. Apart from the O-methyl group at the reducing end of the molecule, the identity and sequence of the five monomeric sugar units contained in fondaparinux is identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate (HS). that can be found within polymeric heparin and heparan sulfate. One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced thrombocytopenia is substantially lower.
Further examples of agents elevating the subject's HGF level include Hepatocyte growth factor activator precursor (EC 3.4.21.-) (HGF activator; HGFA) including Hepatocyte growth factor activator short chain and Hepatocyte growth factor activator long chain.
The exposure to HGF or an HGF elevating agent may be done by applying the substance in question to the subject as known to the skilled practitioner. Methods of administration are detailed in the present description.
In a preferred embodiment of the invention, the mesoangioblast-like cell has been or is obtained from an adult's blood. An adult in the context is of present invention relates to a subject sexual and/or physical mature. Sexual maturity is the age/stage when an organism
can reproduce. Physical maturity is the age/stage at which the subject reaches its maximum height and secondary sex characteristics (e.g. for humans form such as body hair and facial hair, voice lowers in pitch, and menses begin (women)). Especially, for isolation from adult's blood, the prior treatment with HGF or an HGF-elevating agent, particularly HGF. heparin or HGF activator, is envisioned, in order to increase the number of MAB-like cells in the adult's blood.
In another preferred embodiment of the invention, the mesoangioblast-like cell has been or is obtained from a mammal. Examples of mammals include without limitation rat. mouse. cat. dog. horse, pig. cow. rabbit, sheep, goat and particularly primates, especially humans. The human subject may be a child (postnatal being before adolescence as defined above) or an adult. In a particular preferred embodiment of the invention the child or adult is suffering from a cardiovascular disease requiring regenerative treatment, such as cardiac repair.
In a preferred embodiment of the invention the mesoangioblast-like cell may be characterized by the presence and/or absence of particular markers. The presence and absence of these markers may be determined using methods known to the skilled person such as FACS analysis. RT-PCR. immunostaining and/or cytochemical staining. The methods may be carried out e.g. as described in the Examples.
1 he feature negative for a marker refers to the identification of marker on the surface of cells using e.g. FACS analysis or RT-PCR as detailed in the Examples. Preferably, a MAB-like cell is marker negative, if the signal obtained with the respective detection method is below the threshold or not significantly different from the background or the negative control.
The feature positive for a marker refers to the identification of marker on the surface of cells using e.g. FACS analysis or RT-PCR as detailed in the Examples. Preferably, a MAB-like cell is marker positive, if the signal obtained with the respective detection method is above the threshold or significantly increased relative to the background or negative control.
As detailed above, the MAB cell is characterized by the presence of mesenchymal (e.g. CD73 and/or CD 13) and endothelial (e.g. KDR. CDl 05. Tie2 and/or VE-cadherin markers), but lacks the hematopoietric factor CD45.
The mesenchymal marker may be CD73 and/or CD 13. Additionally, the following mesenchymal marker may be present: CD44. Particularly, the presence of the following combinations of these markers may be identified:
- CD73 and CD13, - CD73 and CD44,
- CD13 and CD44. or
- CD73. CD13 and CD44.
The endothelial marker may be KDR (CD309). Tie2, CD 105 and/or VE-cadherin (CD 144). Particularly, the presence of the following combinations of these markers may be identified:
- KDR and CDl 05,
- CD 105 and VE-cadherin.
- KDR and VE-cadherin. - KDR. CD 105 and VE-cadherin.
- KDR, Tie2 and CD105.
- CD 105, Tie2 and VE-cadherin,
- KDR. Tie2 and VE-cadherin. or
- KDR, Tie2 CD 105 and VE-cadherin.
As detailed above, the MAB-like cell is characterized the absence of CD45. Moreover, one or both of the following factors may be absent: CD34 and/or CDl 33. Particularly, the absence of the following combinations of these markers may be identified:
- CD45 and CD133. - CD45 and CD34.
- CD45. CD34 and CD133.
In a still more preferred embodiment of the present invention, the MAB-like cell is characterized by the presence of CD73 or KDR (VEGF-receptor-2). optionally also the presence of one or more markers selected from the group consisting of Oct3/4. Klf4. c-myc and Soxl 7: and the absence of CD45. optionally also the absence CD34 or CDl 33. or
- the presence of KDR. CD73 and CD29 (and optionally also the presence of Oct3/4. Klf4. c-myc and/or Soxl 7): and the absence of CD45. optionally also the absence CD34 or CD133. or the presence of CD73. CD13. CD44. CD144. KDR and CD105 and the absence of CD45, CD34 and CD133. or
- the presence of CD73, KDR and telomerase activity and the absence of CD45: or
- especially the presence of CD73 and KDR (VEGF-receptor-2). optionally also the presence CD44. Klf4. Oct3/4 and CD29. and the absence of CD45. optionally also the absence CD34 and CDl 33. or - especially the presence of CD105. CD144. KDR. CD13, CD73. CD29 and CD44 and the absence of CD34. CD45, CD133 and CD18, or most preferably the presence of CD73. KDR (VEGF-receptor-2). Oct3/4, Klf4, c- myc and Soxl 7. and the absence of CD45. CD34 and CD133.
Additionally, the MAB-like cell may be characterized by the presence of one or more stem cell markers. An example of these markers includes islet- 1. Furthermore, stem cell properties of the cells may be proven by high telomerase activity.
Suitable methods for determining the presence and absence of these factors and marker include flow cytometry, immunohistochemistry and RT-PCR and are described into more detail in the Examples.
In a still more preferred embodiment of the invention, the mesoangioblast-like cell is defined by one or more of the following: i) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to HGF and/or wherein the subject is exposed to 0.01 to 100 μg/kg bodyweight HGF:
ii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to heparin or a functionally active derivative thereof, e.g. a low-molecular- weight heparin, and/or wherein the subject is exposed to 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin; or iii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to a combination of (i) HGF and (ii) heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin, and/or wherein the subject is exposed to (i) 0.01 to 100 μg/kg bodyweight HGF and (ii) 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular- weight heparin.
As detailed above. HGF or an HGF-elevating agent (such as heparin or a functionally active heparin derivative) may be used in order to mediate mobilization on MAB-like cells into the subject's blood. In order to obtain proper mobilization of MAB-like cells, the above regimen with respect to time and or concentration of the agent mobilizing MAB-like cells may be followed.
Particularly, for each of the above regimens i) to iii), the time between agent application and isolating of MAB-like cells may be further specified as 1 h to 72 h after the subject's exposure to the agent, particularly at least 2h to 48 h, preferably 2h to 36 h. more preferably 2h to 12 . even more preferentially 2-6 hours.
Alternatively or additionally, for each of the above regimens i) to iii). the concentration of the agent mobilizing MAB-like cells may be further specified as
- from about 0.01 to about 100 μg/kg bodyweight, particularly from about 0.1 to about 50 μg/kg bodyweight. more preferably from about 1 to about 30 μg/kg bodyweight (particularly for HGF). and/or
- from about 0.01 to about 100 μg/kg bodyweight. particularly from about 0.05 to about 30 μg/kg bodyweight. more preferably from about 0.1 to about 10 μg/kg bodyweight
(particularly for heparin of the functionally active derivative thereof).
However. the skilled practitioner will understand that the above concentrations depend from a variety of factors (species, disease state, age. sex. body weight and difference in sensitivity of the administration object, timing and interval of administration, characteristics, dispensing and kind of the pharmaceutical preparation, the kind of the active ingredient and the like) and will have to be adapted to the prevailing circumstances.
In another preferred embodiment of the invention, the mesoangioblast-like cell is capable of differentiating into a mesoderm-derived cell, particularly into one. two or three cardiovascular lineage(s).
The mesoderm is a one of the three germ layers. During embryogenesis the zygote undergoes rapid cell divisions with no significant growth, producing a blastula. During gastrulation cells migrate to the interior of the blastula. consequently forming three (triploblastic) germ layers. The embryo during this process is called a gastrula. The germ layers are referred to as the ectoderm, mesoderm and endoderm. The germ layers eventually give rise to all of an animal" s tissues and organs through the process of organogenesis. The mesoderm generally gives rise to the following organs or tissues bones, most of the circulatory system, including the heart and major blood vessels, connective tissues of the gut and integuments, mesenchyme, mesothelium, skeletal muscles, peritoneum (lining of the coelom), reproductive system, urinary system (including the kidneys). Accordingly, in a preferred embodiment of the present invention, the mesoangioblast-like cell is capable of differentiating into cells of at least one of these organs or tissues. More preferably, the mesoangioblast-like cell is capable of differentiating into one. two or three cardiovascular lineage(s). A cardiovascular lineage describes cardiovascular cells with a common ancestry, which is developing from the same type of identifiable immature progenitor cell. For example, the functional heart is comprised of distinct mesoderm-derived lineages including cardiomyocytes. endothelial cells and vascular smooth muscle cells. Studies in the mouse embryo and the mouse embryonic stem cell differentiation model have provided evidence indicating that these three cardiovascular lineages develop from a common cardiovascular progenitor that represents one of the earliest stages in mesoderm specification to the cardiovascular lineages. The capability of MAB-like cells to differentiate into several cardiovascular
lineages identify MAB-like cells as a progenitor that defines one of the earliest stages of human cardiac development. Consistently. MAB-like cells express the marker KDR. which defines early cardiovascular progenitor cells in embryonic stem cells (Yang et al. Nature. 2008 May 22:453(7194):524-8).
In one embodiment of the invention the mesoangioblast-like cell may be differentiated into a mesoderm-derived cell, particularly a cardiovascular cell. These cells may be transplanted into the organ or tissue requiring repair or regeneration, e.g. the myocardium. "Differentiation" in the present context refers to a status of cells in which the cells develop specific morphological or functional properties. Cells may "differentiate" into a specific tissue or organ. In the context of cardiovascular cells, "differentiation" refers to develop at least one property of a cell of the cardiovascular system. Typical characteristics of these cells (e.g. smooth muscle cells, endothelial cells and cardiomyocytes) are detailed herein.
The term "organ" refers to two or more adjacent layers of tissue, which layers of tissue maintain some form of cell-cell and/or cell-matrix interaction to form a microarchitecture.
The term "tissue" refers to a group or layer of similarly specialized cells which together perform certain special functions.
In accordance with the present invention the mesoangioblast-like cell may be used for the treatment of a cardiovascular disease and/or an ischemic disease, particularly wherein the cardiovascular and/or ischemic disease is selected from the group consisting of myocardial infarction, heart failure and peripheral vascular occlusive disease. Cardiovascular diseases as well as ischemic diseases often lead to irreversible damages of organs and tissues involved.
The term "'cardiovascular disease" refers to the class of diseases that involve the heart or blood vessels (arteries and veins). While the term technically refers to any disease that affects the cardiovascular system, it is usually used to refer to those related to atherosclerosis (arterial disease). These conditions have similar causes, mechanisms, and treatments.
An ischaemic or ischemic disease is a disease characterized by reduced oxygen supply to the an organ or tissue, usually due to coronary artery disease (atherosclerosis of the coronary arteries). Its risk increases with age. smoking, hypercholesterolemia (high cholesterol levels), diabetes, hypertension (high blood pressure).
Preferred examples include myocardial infarction, heart failure and peripheral vascular occlusive disease.
Another aspect of the present invention relates to a method of isolating a mesoangioblast- like cell from a subject, comprising the steps of: a) optionally exposing a subject to HGF and/or an agent elevating the subject's HGF level; and b) isolating a mesoangioblast-like cell mobilized by step a) from the subject's blood.
The features "MAB-like cell" and "subject" may be as defined above. Additionally, step a) of this method may be carried out as detailed above in the context of the MAB-like cell of the present invention.
After the subject has been exposed to the HGF and/or an agent elevating the subject's HGF level the MAB-like cell is isolated from the subject's blood. For this, a blood sample may be taken from the subject. Particularly for mammals, this may be conveniently performed by taking venous blood from the subject. Venous blood may be obtained by venipuncture from a the mammal, e.g. a human donor, wherein usually only a small sample, e.g. 50 ml to 100 ml sample, of blood is adequate for the method of the present invention (see Examples). Blood is most commonly obtained from the median cubital vein, on the anterior forearm (the side within the fold of the elbow). This vein lies close to the surface of the skin, and there is not a large nerve supply. Most blood collection in the industrialized countries is done with an evacuated tube system consisting of a plastic hub, a hypodermic needle, and a vacuum tube. However, blood may also be obtained by any other method known to the skilled person.
After isolation of the blood. MAB-like cells are isolated from the blood sample. These cells may be isolated on the basis of their characteristic marker profile, as defined above in the context of any of the embodiments of the present invention. This may be done with a fluorescence-activated cell sorting (FACS).
Alternatively, the isolation of MAB-like cells may be done as detailed in the Examples. For this, mononuclear cells (MNCs) may be isolated from blood by any suitable method known by the skilled person e.g. by density centrifugation as density gradient centrifugation using a Ficoll gradient. Thereafter. MNCs may be plated on suitable culture dishes, preferably coated with e.g. fibronectin. and maintained under suitable conditions, which induce the presence of supplemental growth factors. After a suitable time, e.g. after several days such as 7 days, non-adherent cells are discarded. Remaining cells are MAB- like cells (and EPC after Is1 cultivation). These cells may be used or further cultivated under suitable conditions for propagation or in order to obtain differentiated cells. Additionally or alternatively, cells might be sorted by using the marker combinations described above.
After having been obtained and optionally further purified, the cells may be immediately cultivated or frozen for storage as known to the person skilled in the art. The cells may be frozen at liquid nitrogen temperatures and stored for long periods of time, being thawed and capable of being reused. The cells will usually be stored in 10% DMSO. 70% autologous plasma (irradiated with 2500 rad). 20% culture medium. Cells may be frozen in a programmable cell freezer to -180° C in liquid nitrogen. Once thawed, the cells may be expanded by use of growth factors or cells associated with stem cell proliferation and differentiation.
The methods of the present invention may encompass cultivation of cells under suitable conditions. Suitable conditions include an appropriate temperature and gas mixture (typically. 370C. 5% CO2) in a cell incubator. Alternatively hypoxic incubators can be used. Aside from temperature and gas mixture, the most commonly varied factor in culture systems is the culture media including growth medium. The term "culture medium" is recognized in the art. and refers generally to any substance or preparation used for the
cultivation of living cells. Recipes for growth media can vary in pH. glucose concentration, growth factors, and the presence of other nutrient components. The factors used to supplement media are often derived from animal blood, such as calf serum or by a feeder layer. Culture conditions may vary from species to species: however, typical conditions are the following are:
Exemplary procedures for isolating the cells of the invention are as follows: Blood samples may be collected, e.g. from the patients who undergo open heart surgery with cardiopulmonary bypass. Mononuclear cells (MNCs) may be isolated by Ficoll density gradient centrifugation with Biocoll separating solution (Biochrom AG. Berlin. Germany). MNCs are plated in endothelial basal medium (EBM) (CellSystems. St. Katharinen, Germany), with supplements (1 μg/ml hydrocortisone. 3 μg/ml bovine brain extract. 30 μg/ml gentamicin, 50 μg/ml amphotericin B. 10 μg/ml EGF. and 20% fetal calf serum) on culture dishes coated with human fibronectin (Sigma, St Louis. MO). After 7 days in culture, non-adherent cells are discarded and cells are cultured for additional 7 days in same medium. On day 15. cells are detached by 0.25% Trypsin-EDTA (GIBCO) and are seeded at 5χ lO4 cells/ml on fibronectin-coated dishs. When cells reached 80% confluency, cells are subsequently passaged at 5χ 104 cells/ml and are used for following analyses.
Alternatively. X-vivo medium + autologous serum can be used. Mononuclear cells may be suspended in X vivo- 15 medium (Biowhittaker) supplemented with 1 ng/mL carrier- free human recombinant VEGF (R&D), 20% human serum and potentially with 0.1 μmol/L atorvastatin from each individual patient. Cells are seeded at a density of 6.4x10 cells/mm" at fibronectin-coated dishes (Roche).
Suitable conditions are also given in the Examples.
Still another aspect of the present invention relates to a method of producing a mesoderm- derived cell, comprising the steps of: a) optionally exposing a subject to HGF and/or an agent elevating the subject's HGF level: b) isolating a mesoangioblast-like cell mobilized by step a) from the subject: and
c) differentiating the mesoangioblast-like cell into a mesoderm-derived cell.
Steps a) and b) of the method of the invention of producing a mesoderm-derived cell may be carried out as detailed above in connection with the method of isolating a mesoangioblast-like cell from a subject.
In step c) the MAB-like cells are differentiated into a mesoderm-derived cell, e.g. by addition of suitable factors inducing differentiation into the desired mesoderm-derived cell. Examples of suitable mesoderm-derived cells include without limitation endothelial cell, a smooth muscle cell, a cardiomyocyte, an osteoblast, an pericyte, a fibroblast, and a myofibroblast.
In preferred embodiment of the invention the mesoangioblast-like cell may be further characterized as detailed above in the context of the MAB cells of the present invention. This is particularly true for the use of heparin as HGF elevating agent, for the characterization of the subject from which the MSB-like cell is derived, for the presence and/or absence of particular markers as defined above and for the conditions for exposure to an HGF elevating agent.
In a further embodiment of the invention the mesoderm-derived cell is an endothelial cell, a smooth muscle cell, a cardiomyocyte or an osteoblast.
In a further embodiment of the present invention, the above method comprises expanding, particularly clonally expanding the mesoangioblast-like cell isolated in step b).
In a preferred embodiment the differentiating of step c) may be carried out by incubating the mesoangioblast-like cell in the presence of a differentiation factor or a cell producing such factors (e.g. a cardiomyocyte for differentiation into cardiac cells (see Examples)). Suitable conditions for inducing differentiation into - endothelial cells include the use of Matrigel Basement Membrane Matrix (BD
Bioscience). - smooth muscle cells include the presence of TGFβ or FGF8.
- cardiomyocytes include presence of neonatal cardiomyocytes.
- cardiomyocytes induced by Wnt3a and dexamethason.
- cardiomyocytes induced by Jagged- 1.
- cardiomyocyte induced by Azacytidin.
Suitable conditions are also detailed in the Examples.
A further aspect of the present invention relates to the use of a mesoangioblast-like cell of the present invention for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease, wherein the mesoangioblast-like cell has been obtained from a subject's blood, optionally after having been exposed to hepatocyte growth factor (HGF) and/or an agent elevating the subject's HGF level. If the medicament comprising the MAB-like cells is administered to the recipient, the cells will be applied to or migrate mainly to a target tissue or organ, e.g. an tissue or organ to be repaired. In the environment of this tissue or organ, new cells forming or regenerating the organ or tissue will be generated by differentiating the cells of the MAB-like cells into the respective cells, e.g. cardiomyocytes.
Still another aspect of the invention relates to a method of for treating a cardiovascular disease and/or an ischemic disease comprising administering to a subject an effective amount of MAB-like cells of the present invention. The specific therapeutically effective amount of cells for any particular subject will depend upon a variety of factors including the condition or disease the subject is suffering from, the route of administration, the age, body weight and sex of the patient, the duration of the treatment and like factors well known in the medical arts.
In preferred embodiment of the invention the mesoangioblast-like cell may be further characterized as detailed above in the context of the MAB cells of the present invention. This is particularly true for the use of heparine as HGF elevating agent, for the characterization of the subject from which the MSB-like cell is derived, for the presence and/or absence of particular markers as defined above, for the conditions for exposure to
an HGF elevating agent, for the differentiation capacity, for the differentiation status and for its use as medicament, especially for the diseases as defined above.
A final aspect of the present invention relates to a method of converting the mesoangioblast-like cell of the present invention (as defined in any of the above embodiments) into an inducible pluripotent stem cell-like cell, wherein the level of Sox2 protein in the mesoangioblast-like cell is increased, particularly wherein the increase is mediated by: a) transfecting the mesoangioblast-like cell of the present invention with the Sox2 gene and expressing the same: b) transducing the mesoangioblast-like cell of the present invention with the Sox2 protein: and/or c) activating a promoter directing the Sox2 gene expression in the mesoangioblast-like cell of the present invention.
The cells obtained by the above method, i.e. the inducible pluripotent stem cell-like cell, have similarity to iPCs, particularly in that they have increased plasticity and increased regenerative cardiovascular potency. Therefore, they are referred to as inducible pluripotent stem cell-like cells.
Adult (or somatic) stem cells are cells found in most, if not all. multi-cellular organisms. They are characterized by the ability to renew themselves through mitotic cell division and differentiating into a diverse range of specialized cell types. In postnatal or adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialized cells, but also maintain the normal turnover of regenerative organs, such as blood, skin or intestinal tissues. Inducible pluripotent stem cells, commonly abbreviated as iPS cells or iPSCs. are a type of pluripotent stem cell artificially derived from a non- pluripotent cell, typically an adult somatic cell, by inserting certain genes. Induced pluripotent stem cells are believed to be identical to natural pluripotent stem cells, such as embryonic stem cells, in many respects such as the expression of certain stem cell genes and proteins, chromatin methylation patterns, doubling time, embryoid body formation, teratoma formation, viable chimera formation, and potency and differentiability, but the
full extent of their relation to natural pluripotent stem cells is still being assessed. Inducible pluripotent stem cells are in general generated by the following method: (1) Isolation and cultivation of donor cells. (2) Transfection of cells with stem cell-associated genes (e.g. colored cells may indicate the cells expressing the exogenous genes). (3) Harvest and cultivation of the cells according to ES cell culture, e.g. using mitotically inactivated feeder cells. (4) Usually, a small subset of the transfected cells becomes iPS cells and generates ES-like colonies.
In the present invention the expression of Sox2 in the MAB-like cells is low as compared to embryonic stem cells. Accordingly. iPS-like cells may be produced by elevating the cells Sox-2 level, which may be achieved by a) transfecting the mesoangioblast-like cell of the present invention with the Sox2 gene and expressing the same: b) transducing the mesoangioblast-like cell of the present invention with the Sox2 protein: and/or c) activating a promoter directing the Sox2 gene expression in the mesoangioblast-like cell of the present invention.
After some time (e.g. after 3-4 weeks), small numbers of transfected cells begin to become morphologically and biochemically similar to pluripotent stem cells, and are typically isolated through morphological selection, doubling time, or through a reporter gene and antibiotic infection.
Additionally, the MAB-like cells or iPSs may be genetically modified. This may be of particular interest in order to study the function and activity of a particular gene of interest (e.g. during embryonic development) or in order to produce animals with desired properties (e.g particular productive farm animals) resulting from the presence of a transgene or absence of a particular gene.
It is noted that also mesoderm-derived cells, as well as iPSs may be used as medicament as detailed for the MAB-like cells of the present invention.
The following figures and examples are offered by way of illustration and not by way of limitation.
FIGURES
Figure 1
(A) Population doubling of cells isolated of 12 different donors. Square : under 1 year old: triangle : 1 -3 years: circle : over 10 years old. (B) Single regression analysis between age and population doublings. (C) Telomerase activity of 1st and 15th passage. n=l l (1st passage). n=4 (15sl passage). (D) Flow cytometry analysis of child-derived cells. Isotype IgG served as control. Mesenchymal markers, CD 13, CD73, CD44 are positive. Hematopoietic markers. CD34. CD45, CDl 17. and CDl 33 are negative. Some endothelial markers, such as KDR, CD105 are positive. (E) RT-PCR of stem cell markers. Cells were isolated from 5 different donors. Mouse embryonic stem cells (ES cells) are used as positive control. Samples without reverse transcriptase (-RT) and H2O served as negative control. (F) Expression of markers in representative single cell-derived clones. (G) Number of single cell-derived clones expressing the respective marker.
Figure 2
(A-B) Endothelial differentiation in vitro (A; morphology) and in vivo (B; Hematoxilin Eosin staining) using matrigel plug assays. (C) RT-PCR of FH-I and HEX in peripheral blood-derived circulating mesoagioblasts (cMAB) isolated from 2 children. MAB obtained from human aorta, human heart, and HUVEC are shown. H2O served as negative control. (D) RT-PCR of α-myosin heavy chain (α -MHC) and GAPDH of cMAB. Wnt3a and dexamethasone was used to induce cardiac differentiation. (E) RT-PCR of several transcription factors of cells isolated of 5 different donor-derived cMAB is shown. Human or rat embryonic heart are used as positive control. -RT and H2O served as negative control.
Figure 3
CeIl mediated functional recovery in a hind limb ischemia (A), and myocardial infarction (MI) model (B-D) using nude mice. (A) IxIO6 of children-derived cMABs were injected intramuscularly after ischemia and function was analyzed 2 weeks after operation. Summary of Doppler flow data in cMAB or PBS control group. n=4 (PBS) and 7 (cMAB). * p<0.05. (B-C) Pressure-volume loop analysis using Millar catheter was performed. Representative pressure-volume curve (B) and quantification (C) are shown. * indicates p< 0.01 vs sham. # and ## indicates p< 0.05 and p<0.01 vs MI PBS group, respectively. n=3 (sham), n=7 (PBS), and n=6 (cMAB). (D) Human specific RT-PCR of Tie2, troponin T, and GAPDH in heart injected with cMAB or PBS.
Figure 4
(A) RT-PCR of CD45, KDR, and CD73 in cultivated cells, which were obtained from children or adults undergoing heart surgery with cardiopulmonary bypass. (B-C) Representative cytokine arrays (B) and quantification (n=4) (C) are shown. Serum levels of pre-operation (pre) and post-operation (post) are examined. Gray square indicates hepatocyte growth factor (HGF). * p< 0.05 vs pre-operation. (D) RT-PCR of the HGF receptor c-Met and GAPDH in children-derived cells from 5 different donors. (E) c-Met expression by FACS. (F) Colony number derived from mononuclear cells per 10 ml rat blood after 2 weeks in culture. HGF (l μg/kg; n=5) or PBS (n=14) was administered in rats intravenously and mononuclear cells were obtained after 24 hours. (G) RT-PCR of rat CD45, KDR, and CD73. Cells were obtained from rats after injection of HGF.
EXAMPLES
Methods
Cell isolation & culture from human peripheral blood: The ethics review boards of the universities Giessen and Marburg, and Frankfurt approved the protocol, and the study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from each patient or patient's parent. Blood samples were collected from the patients who underwent open heart surgery with cardiopulmonary bypass. Patients with
known genetic disorder such as troponin mutation, Down syndrome, or CATCH22 were excluded. Total mononuclear cells (MNCs) were isolated by Ficoll density gradient centrifugation with Biocoll separating solution (Biochrom AG, Berlin, Germany). MNCs were plated at 8* 106 cells/ml on a fibronectin-coated dish in endothelial basal medium (EBM) with supplements (1 μg/ml hydrocortisone, 3-12 μg/ml bovine brain extract, 30-50 μg/ml gentamicin, 50 μg/ml amphotericin B, 10 μg/ml EGF, and 20% fetal calf serum). After 7 days in culture, non-adherent cells were discarded and cells were cultured for additional 7 days in same medium. On day 15, cells were detached by 0.25% Trypsin- EDTA (GIBCO) and were seeded at 5>< 104 cells/ml on fibronectin-coated dishes. When cells reached 80% confluency, cells were subsequently passaged at 5>< 104 cells/ml and were used for following analyses. Adult cells were also obtained from patients undergoing open heart surgery with cardiopulmonary bypass (n=5). In order to compare serum levels and cells before and after cardiopulmonary bypass, we collected 2ml blood from children before heart operation. Adult blood from healthy volunteers (n=5) was used for the control experiments.
Alternatively, X-vivo medium + autologous serum can be used. Mononuclear cells were suspended in X vivo- 15 medium (Biowhittaker) supplemented with 1 ng/mL carrier- free human recombinant VEGF (R&D), 0.1 μmol/L atorvastatin (provided by Pfizer), and 20% human serum drawn from each individual patient. Cells were seeded at a density of 6.4x105 cells/mm2 at fibronectin-coated dishes (Roche).
Single cell cloning: For single cell cloning, cells of 2nd-3rd passage were labelled with CM- DiI (Invitrogen) and seeded at a single cell density on fibronectin-coated 96well plates. Single-cell deposition was confirmed microscopically and wells containing more than one cell were excluded.
Other cells: Human umbilical vein endothelial cells (HUVEC) were purchased from Cambrex and cultured in endothelial basal medium supplemented with 1 μg/mL hydrocortisone, 12 μg/mL bovine brain extract, 50 μg/mL gentamicin, 50 ng/mL amphotericin-B, 10 ng/mL epidermal growth factor and 10% fetal bovine serum. Mesenchymal stem cells (MSCs) were isolated by density-gradient centrifugation with
Ficoll from bone marrow of healthy human volunteers. Immediately after isolation, cells were maintained in Mesencult medium (StemCell Technologies, Germany). The CD34+ hematopoietic progenitor cells were isolated from human peripheral blood by immunomagnetic purification. Human mesoangioblasts were obtained from the tissue of ascending aorta from explanted heart in collaboration with Dr. G. Cossu (A. Dellavalle et al., Nat Cell Biol 9, 255-67 (2007)). Aortic tissue was explanted on gelatin-coated dishes and outgrowth cells were used for the experiments.
Hind limb ischemia, cell injection and functional evaluation: The in vivo angiogenic capacity was examined in a unilateral hind limb ischemia model using 8- to 10-week-old athymic ΝMRI nude mice (Harlan, Borchen, Germany). The proximal portion of the right femoral artery including the superficial and the deep branch and the distal portion of the saphenous artery were occluded with an electrical coagulator. Then I x IO6 cells in 50 μl PBS were injected intramuscularly at 4 different sites. The overlying skin was closed by using surgical staples. After 2 weeks, we determined the ischemic (right)/nonischemic (left) limb blood flow ratio by using a laser Doppler blood flow imager (Laser Doppler Perfusion Imager System, moorLDI-Mark 2; Moor Instruments, Wilmington, DE). Data are expressed as the ratio of ischemic to nonischemic hind limb.
Myocardial infarction, cell injection and functional evaluation: Myocardial infarction was induced by permanent ligation of the left coronary artery in 10- to 12-week-old athymic ΝMPJ nude mice (Harlan). Soon after iigation, l *106 cells or PBS (both 50μl) were injected intramuscularly into the border zone at 3 different sites. On day 14 or day 28 (Sox2 transduction), cardiac catheterization was performed for functional analysis by using 1.4F micromanometer-tipped conductance catheter (Millar Instruments Inc). Left ventricular (LV) pressure and its derivative (LV dP/dt) were continuously monitored with a multiple recording system. All data were acquired under stable hemodynamic conditions.
Mobilization of mesoangioblasts-like cells into circulation: We intravenously injected l μg/kg recombinant human hepatic growth factor (rhHGF) or PBS into Lewis Rats. We collected 2-8 ml peripheral blood (PB) from each rat. Cell isolation and culture was performed as described for human cells.
Flow cytometry: Following antibodies (Abs) were used for fluorescence activated cell sorting (FACS): Phycoerythrin (PE)-conjugated anti-CD13, CD14, CD31, CD34, CD44, CD45, CD73, CD146 (BD Biosciences), CD 105, CD144, KDR (R&D), CD133 (Miltenyl Biotec), Fluorescein (FITC)-conjugated anti-CD117 (Santa Cruz), biotinylated c-Met, Allophycocyanin (APC)-conjugated streptavidin, and i so type-matched PE, FITC, or APC- conjugated mouse immunoglobulins. Samples were analyzed by a flow cytometer, BD FACS Calibur cell sorter (BD Biosciences, San Jose, CA).
RT-PCR: Total RNAs were isolated by using TRIzol (Invitrogen) or RNeasy Mini Kit (Qiagen). RNA was subjected to RT-PCR by using Superscript First Strand Synthesis System (Invitrogen). The primer sequences are available upon request. For subcloning and sequencing RT-PCR products were purified by Gel Extraction kit (Qiagen) and were subcloned by using pGEM-T Easy vector (Promega) and 6 clones were collected. Each clone was amplified and sequences were analyzed (SeqLab, Germany).
Quantitative RT-PCR: Quantitative RT-PCR was performed on LightCycler 1.2 (Roche Diagnostics) or StepOnePlusTM Real Time PCR System (Applied Biosystems).
Chromatin immunoprecuipitation (ChIP) Assay: For each immunoprecipitation, approximately 5x106 cells were crosslinked with 1% formaldehyde for 5 min. at room temperature and quenched by addition of glycine (1.25M). The cell lysate was sonicated by using a Branson 450 Sonifier with 4 pulses for 5 sec. with 30% Output to sheer chromatin- DNA complex. For histone ChIPs, EZ ChIP kit (Upstate Biotechnology) was used and followed the manufacturer's protocols. In this assay, 5 μg of AcetylH3 (06-599 Upstate), H3K9me3 (07-442 Upstate), H3K27me3 (07-449 Upstate), H3K4me3 (07-473 Upstate), and lμg of IgG(13-371B Upstate), were used. The total input or immunoprecipitated DNA was determined by quantitative RT-PCR with the equation. ΔCt (threshold cycle) of each sample = mean of Ct(antibody) - mean of Ct(input). Primers are listed below.
Telomerase activity: Telomerase activity was measured with a Telomerase ELISA Assay Kit (Millipore) according to the manufacturer's instructions. Ix 106 cells were used for each experiment.
In vitro Osteogenic, endothelial smooth muscle, and cardiac differentiation assay in vitro: Several differentiation assays were performed as summarized in Table 1. Endothelial differentiation using eNOSp-GFP transduced cells with or without Sox2 transduction was induced by culturing in endothelial differentiation medium as summarized in Table S3 for 7 weeks.
Table 1 : In vitro differentiation assay of children derived circulating mesoangioblasts- like cells for osteoblasts, smooth muscle cells (SMC), and cardiomyocytes (CM). (Stimuli, matrixes, medium, and duration of the cultivation are indicated)
Alkaline phosphatase (ALP) expression was confirmed by StemTAG™ Alkaline Phosphatase Activity Assay Kit (Cell Biolabs Inc.) according to the manufacturer's instructions. Immunofluorescence was performed to confirm smooth muscle cells (SMC) differentiation using anti-smooth muscle actin (SMA) antibody after 14 days of culture.
To induce cardiac differentiation, cells were co-cultured with neonatal cardiomyocytes (CM) for 6 days as previously described with a minor change (C. Badorff et al., Circulation 107, 1024-32 (2003); M. Koyanagi et al., J Biol Chem 280, 16838-42 (2005)). In brief, cells were added onto CM at a ratio of 1 :6 two days after CM isolation. After 6 days, cells were used for detection of cardiac marker gene expression. Alternatively, cells were cultured on non-coated dishes and Wnt3a (100 ng/ml) and dexamethasone (1OnM) were added without co-culturing rat CM. hi addition, αMHCp-GFP cells were cotransduced with or without Sox2 and cells were cultured on gelatine coated dishes in cardiomyocytes conditioned medium. After 7 days, GFP expressions were analyzed by flow cytometry.
Tube Formation Assay (In Vitro Matrigel Plug Assay): Cells (2x105) were cultured in a 12-well plate (Greiner) coated with 200 μL of Matrigel Basement Membrane Matrix (BD Biosciences). Tube length was quantified after 48 hours by measuring the cumulative tube length in four random microscopic fields with a computer-assisted microscope using the program KS300 3.0 (Zeiss).
In Vivo Matrigel Plug Assay: This assay was performed as described previously (A. Kuehbacher, C. Urbich, A. M. Zeiher, S. Dimmeler, Circ Res 101, 59-68 (2007)). Briefly, CM-DiI (Invitrogen) labeled cells (l χl O6) were resuspended in 30 μl PBS and mixed with 500 μl of Matrigel Basement Membrane Matrix (BD Biosciences) containing 15 U of heparin (Sigrna-Λϊdrich). The cell-inairigei mixture was injected subcutaneously into 6- to 8-week-old female athymic nude mice (Harlan) along the abdominal midline. After 7 days, blood vessel growth in Matrigel plugs was quantified by analysis of CD31 -stained sections using microscopy. For hemoglobin analysis, the Matrigel plug was removed after 7 days and homogenized in 130 μL of deionized water. After centrifugation, the supernatant was used in the Drabkin assay (Sigma-Aldrich) to measure hemoglobin concentration. Stock solutions of hemoglobin are used to generate a standard curve. Results are expressed relative to total protein.
Histological analysis: For morphological examination, the hearts of the mice and Matrigelplugs were fixed with 10% buffered formalin and embedded in paraffin, processed
for light microscopy, and stained with hematoxylin and eosin. Alternatively, the hearts of mice and Matrigelplugs were embedded in optimal cutting temperature compound (O. C. T. compound), and were quickly frozen in liquid nitrogen and cut in 5 μm sections.
Immunostaining: For immunohistochemistry of cultured cells, cells were fixed with 4% paraformaldehyde. After permeabilization with 0.2% saponin (Sigma), cells were incubated with the respective antibodies (CD31 ; Chemicon, smooth muscle actin; Sigma, alpha sarcomeric actinin; Sigma, GATA4; Santa Cruz, Nkx2.5; Santa Cruz, Oct3/4; Cell Signaling, IsI-I; R&D, nanog; Abeam, Sox2; Abeam, nestin; Abeam, Cytokeratin 18 (CKl 8); Chemicon). The specimens from frozen tissue sections were fixed with 4% paraformaldehyde, followed by staining with the respective antibodies (human nuclear antigen; Chemicon, smooth muscle actin; Sigma, alpha sarcomeric actinin; Sigma). Nuclei were counterstained with To-pro-3 iodide, Sytox Blue (both Molecular Probes) or DAPI according to the manufacturer's instructions. The images were recorded by confocal microscope (LSM510-META, Carl Zeiss, Oberkochen, Germany).
Immunoblot Analysis: cMABs and MSC were lysed with lysis buffer (Cell Signaling) containing ImM phenylmethanesulfonyl fluoride. After centrifugation the supernatants were collected and subjected to electrophoresis in 10% SDS-polyacrylamide gels. Proteins were transferred to poly vinylidene difluorid membrane, and incubated with anti-Tie2 (BD), anti-nanog (Abeam), anti-Oct3/4 (Oct4A, Cell Signaling), anti-Klf4 (Abeam), anti- myc (Santa Cruz), anti-Sox2 (Abeam), or anti-beta actin (Sigma) overnight at 4 0C. Bound antibodies were visualized by using horseradish peroxidase (HRP)- conjugated sheep anti- mouse or donkey anti-rabbit antibody (both Amersham).
Fluorescence in situ hybridization: For fluorescence in situ hybridization 6 μm sections were prepared from formalin-fixed, paraffin-embedded tissue blocks according to standard procedures. After deparaffinization sections were submitted to heat-induced epitope retrieval by boiling for 22 minutes in 1 mmol/L sodium citrate buffer (pH 8.0). Sections were fixed with 1% paraformaldehyde/PBS on ice for 10 minutes. The human AIu probes were used for fluorescence in situ hybridization (FISH) (C. Bearzi et al., Proc Natl Acad Sci U S A 104, 14068-73 (2007)). Probes were dehybridi sized for 4 min. at 71°C before
incubation of probes with samples (4 min. at 80°C). Overnight hybridization at 37°C was followed by a stringent wash (2χ SSC with 50% formamide 2 times for 10 minutes, 2 x SSC for 5 minutes, NP-40 /2 x SSC for 5 minutes, 2 x SSC for 5 minutes at 42°C). Sections were blocked for 30 minutes with bovine serum albumine and incubated with antibodies against smooth muscle actin (mouse IgG, 1 :400, DAKO) for 1 hour. After washing cells were incubated with Alex Fluor 647-conjugated secondary antibodies (1 :200) (donkey anti-mouse IgG, Molecular Probe). Nuclei were stained with DAPI (DAPI Mounting medium, Vector Laboratories) or Cytox blue (1 :2000, Molecular Probes). All staining were detected using confocal microscopy (Zeiss LSM510 system, Germany).
Cytokine Array: Patient's serum was analyzed by using a cytokine antibody array from RayBio Human Cytokine Antibody Array (RayBiotech, Inc, Norcross, Ga) according to the manufacturer's instructions. A semiquantitative analysis of the comparative intensity of the spots was performed with an image analysis program (TINA; version 2.09g).
Primer list: PRIMER NAME PRIMER SEQUENCE SEQ ID NO: h-GAPDH-for GAAGGTGAAGGTCGGAGTC 1 h-GAPDH-rev GAAGATGGTGATGGGATTTC 2 hmr-GAPDH-for CAGAAGACTGTGGATGGCCC 3 hmr-GAPDH-rev AGTGTAGCCCAGGATGCCCT 4 hm-Nanog-for CAGCCCTGATTCTTCCACCA 5 hm-Nanog-rev GTTCTTGCATCTGCTGGAGG 6 hm-Oct3/4-for GAACATGTGTAAGCTGCGGC 7 hm-Oct3/4-rev TTCTGGCGCCGGTTACAGAA 8 hm-KLF4-for CCCACATTAATGAGGCAGCC 9 hm-KLF4-rev TGGGGGAAGTCGCTTCATGT 10 hm-cMyc-for AACGACAGCAGCTCGCCCAA 11 hm-cMyc-rev TTGAGGACCAGTGGGCTGTG 12 hm-SOX17-for ATACGCCAGTGACGACCAGA 13 hm-SOX17-rev TAGTTGGGGTGGTCCTGCAT 14 hm-Sox2 for AGATGCACAACTCGGAGATCAGC 15
hm-Sox2 rev GCCGTTCATGTGCGCGTAACTGTC 16 hm-CD45 for CCAGGAAATACATTGCTGCACAAG 17 hm-CD45 rev TCGCCTTAGCTTGACAACATAACC 18 h-KDR-for CTCTGCCAATCCATGTGGGA 19 h-KDR-rev CGTGCATGAGACTTCGATGC 20
CD73 for TGATCGAGCCACTCCTCAAAGAG 21
CD73 rev CTCTTTGGAAGGTGGATTGCCTG 22 h-Flil-for ATCAGCCAGTGAGGGTCAAC 23 h-Flil-rev GGCCATTCTTCTCGTCCATA 24 hm-HHEX-for ACCATCGAGCTGGAGAAGAA 25 hm-HHEX-rev TGCTTTGAGGGTTCTCCTGT 26 hTropT Exon9 for GAAGAAGAAGAGGAAGCAAAGGAG 27 hTropT Exon9 rev TCCTTCTCCCGCTCATTCC 28
Islet- 1 -for AGTGTAATCAGTATTTGGACGAGAG 29
Islet- 1 -rev TAGCAGGTCCGCAAGGTGTGCAG 30 h-Nkx2.5-for CACCGGCCAAGTGTGCGTCT 31 h-Nkx2.5-rev CCGCGTTGTCCGCCTCTG 32 h-GATA4-for GACGGGTCACTATCTGTGC 33 h-GATA4-rev CACTACCTGAAGGAGCTGC 34
MK-hTbx5-for CCACAGCTGGGAGAGGGAAT 35
MK-hTbx5-rev CAACTCCGTGCACAGAGTGG 36
MK-hMEF2C-for CATCTGGTTGGTTTTCAGCC 37
MK-hMEF2C-rev CGGATGACAAAGCAACTATCC 38 h-Tie2-for AGCTGCAACAATGGGGAGAT 39 h-Tie2-rev TGTTGCCAAGCCTCATAGTG 40 h-a-MHC-for GTCCCGGCAGCTAGAGGA 41 h-a-MHC-rev CCTCTGTCTCCTCCTCGTAC 42 r-CD45-for CCACCAGGGACTCACAACTT 43 r-CD45-rev GTAGAGGACTTCCGCAGCAC 44 r-CD73-for ATGCCTTTGGCAAATACCTG 45 r-CD73-rev GGTTTCCCATGTTGCACTCT 46 r-KDR-for CCAAGCTCAGCACACAAAAA 47
r-KDR-rev CCAACCACTCTGGGAACTGT 48 rGAP-for TTGTGATGGGTGTGAACCAC 49 rGAP-rev GGATGCAGGGATGATGTTCT 50 h-CD34-for CACCCTGTGTCTCAACATGG 51 h-CD34-rev GGCTTCAAGGTTGTCTCTGG 52 CS-CD 13 for ACAGCCAGTATGAGATGGACAGC 53 CS-CD 13 rev CCATTGGATGCCTGCTTCTTCAC 54 h-CD14 for GCCGCTGGTGCACGTCTCTGC 55 h-CD14 rev GGCTTCCAGAGGCAGCGGAGG 56 CD 18 for GCCCCAACAAGGAGAAAGAGTGC 57 CD 18 rev CGATGGGTAGTCGAATTCGTTGC 58 CD29 for CCTTACATTAGCACAACACCAGC 59 CD29 rev TTTTTCAGCTCCTTGTAAACAGGC 60 CD31 for GGATCATTTCTGGGATCCATATGC 61 CD31 rev GCAGATATACGTCCCACTGTCCG 62 CD44 for AGAAAGCTCTGAGCATCGGATTTG 63 CD44 rev TGTAACCTCCTGAAGTGCTGCTC 64 CD 105 for CATCGACGCCAACCACAACATGC 65 CD 105 rev TGCACTTCAAATGCGCAACAAGC 66 CDl 17 for ATTCCCCAAACCTGAACACCAGC 67 CDl 17 rev CAAAAATACCAATCTATTGTGGGC 68 CD 133 for ATCAAAAGGAGTCGGAAACTGGC 69 CD 133 rev TTGGTGCAAGCTCTTCAAGGTGC 70 VE-Cad-for AGGTATGAGATCGTGGTGGAAGC 71 VE-Cad-rev TGGATGTATTCATAATCCAGAGGC 72 CD 146 for AAGATGCCCAGTTTTACTGTGAGC 73 CD 146 rev GTTCCTGTGGTTCACTCAGCAGC 74 h-NG2-CSPG4-for TGCTGCAGCTCTACTCTGGA 75 h-NG2-CSPG4-rev CTGAGGAGGCGTTCAGAAAC 76 c-met for GCCTGAATGATGACATTCTTTTCG 77 c-met rev GCGACCCTCTGATGTCCCAAGAT 78 ChIP KLF4 for GCTGCTGAGTGGAAGAGAGC 79
ChIP KLF4 rev AATTGGCCGAGATCCTTCTT 80 hOCT3/4-ChIP-S2 TTGCC AGCCATT ATCATTCA 81 hOCT3/4-ChEP-AS2 TATAGAGCTGCTGCGGGATT 82 hSOX2-ChIP-Sl GAGAAGGGCGTGAGAGAGTG 83 hSOX2-ChIP-ASl AAACAGCCAGTGCAGGAGTT 84
SEQ ID NO: 81 and 83: cf. K. Takahashi et al., Cell 131, 861-72 (2007) Preparation of Lentiviral Stocks: Preparation of (lentiviral) stocks were performed as described (Ziebart et al., 2008, CircRes 103, 1327-1334). In brief, self inactivating lentiviral vectors containing the enhanced green fluorescent protein (GFP) gene, alpha myosin heavy chain (MHC) promoter (accession number: U71441) GFP, eNOS promoter (accession number: AF387340) GFP, or the human SOX2 gene and a WPRE (woodchuck posttranscriptional regulatory element) under the control of a spleen focus-forming virus promoter were generated by transient transfection of 293T cells using pCMVΔR8.91 as packaging plasmid and pMD2.G for vesicular stomatitis virus-G protein (VSV-G) pseudotyping. After 8 hours, the medium was replaced by EBM supplemented with EGM SingleQuots and 20% FBS. The supernatant was collected every 24 hours for 2 days, pooled (200 to 250 mL), and filtered through 0.22-μm filters.
Lentiviral Transduction: For lentiviral transduction, isolated cells were transduced at 2nd - 3rd passages. Transduction was carried out by adding viral supernatant to the EBM supplemented with EGM SingleQuots and 20% FBS. After 6 hours, medium was changed and the cells were transduced a second time.
Echocardiography: In order to control initial infarct size and check the left ventricular function, we performed echocardiography analysis (Visualsonics; Vevo770). Initial infarct size was evaluated by left ventricular diastolic dimension (LVDd) and wall motion score index (Zhang et al., 2007, Am J Physiol Heart Circ Physiol 292, Hl 187-1192) soon after coronary ligation. Echocariography was performed by a blinded single observer.
Statistics: Data are expressed as mean +_SEM. Unpaired two-tailed student's t-test, Mann- Whitney U-test (to compare 2 groups) or ANOVA (> 3 groups) were used for the comparison between groups based on the original data. Single regression analysis was performed to investigate the relation of donor age and population doubling.
EXAMPLE 1 : Identification of MAB-like cells from peripheral blood of children
Circulating progenitor cells contribute to neovascularization and have been used for cell therapy of ischemia. Endothelial progenitor cells (EPC) isolated from adult blood are characterized by coexpression of hematopoietic and endothelial markers, analogue to the hemangioblast. In contrast, in embryonic development, vessel-associated multipotent progenitors, the so called mesoangioblasts (MAB), have been experimentally described.
MAB express the key marker of angiopoietic progenitors, KDR, as well as mesenchymal markers.
hi order to assess the phenotype and functional properties of circulating progenitors during postnatal development, we isolated cells from peripheral blood of children between 8 days and 2.5 years after birth and compared these cells with adult EPC. For this, isolated mononuclear cells were plated on fibronectin-coated dishes in EBM medium supplemented with growth factors.
At day 14, adherent cells derived from children demonstrated expression of mesenchymal markers CDl 3, CD73, the endothelial markers CD 105, KDR and VE-cadherin, but were negative for hematopoietic markers CD 133 and CD45 as documented by FACS analysis and RT-PCR (figure Id/data not shown), hi contrast, adult EPC did express hematopoietic and endothelial markers, but lacked expression of CD73 (table 2). Thus, the children- derived circulating progeniors (ChCP) resemble the previously described multipotent MAB. Indeed, ChCP could be induced to differentiate to cardiomyocytes, smooth muscle cells, and osteoblasts (figure 2/data not shown). Moreover, ChCP did express the stem cell markers islet-1 and c-kit and showed a marked proliferative capacity (28.3+0.9 passages, 64.0+2.9 population doublings) before entering a senescent state. Population doubling was
strongly correlated with age of donors (R2=0.824, p=0.0001). Consistently, ChCP had a high telomerase activity (OD 0.6+0.1) and secreted high levels of cytokines such as HGF, VEGF, and SDF-I (figure I/data not shown). These data identify a novel circulating progenitor cells, which can be isolated during postnatal development in humans. These ChCP resemble the previously described multipotent MAB during embryonic development, exhibit a high proliferative capacity and express various functional stem cell markers. These progenitors might be well suited for cell therapeutic strategies.
EXAMPLE 2: Circulating mesoangioblasts differentiate into cardiac myocytes and improve function after acute myocardial infarction
The cells described in Example 1 were tested for their potential of cardiac differentiation For this, we tested the capacity of children-derived MAB to acquire a cardiomyogenic phenotype.
MAB expressed several cardiac transcription factors such as Nkx2.5, GAT A4 and MEF2C and the stem cell marker islet- 1 (figure 2e). In order to assess cardiac differentiation capacity, we performed co-culture assays with neonatal rat cardiomyocytes (CM). Immunochemical analysis revealed that MAB expressed cardiac α-sarcomeric actinin 6 days after co-culture (data not shown). Moreover, human troponin T (TnT) was expressed as demonstrated by human specific RT-PCR (data not shown). To confirm these data, we examined TnT expression in MAB isolated of a 2-year old patient with a known mutation of TnT. Sequences of the cloned RT-PCR products were identical to human TnT except for the known mutation providing genetic proof of concept for cardiac differentiation. In order to exclude fusion between MAB and CM as a mechanism, we used paraformaldehyde-fϊxed CM as scaffold. In this assay, human TnT also was detected, indicating that differentiation is sufficient to induce cardiac markers gene expression. Next, we tested the effect of MAB to improve cardiac function. MAB was injected intramuscularly in nude mice after myocardial infarction. Functional analysis using Millar catheter 2 weeks after infarction demonstrated that cell therapy lowered filling pressure and preserved diastolic function when compared with PBS injected group (LVEDP: -
20.3%, tau: -20.6%, vs PBS injected heart). Furthermore, left ventricular volume was also decreased (LVEDV/weight -27.3%) (figure 3).
In summary, children-derived MAB express cardiac-specific genes after co-culture with CM and improved cardiac function in vivo. Given that MAB can be easily isolated and expanded from peripheral blood, these cells might be suitable to augment cardiac repair in children with heart failure.
EXAMPLE 3: Adult circulating progenitor cells for cardiovascular regeneration
Cell therapy is an option to improve cardiac function of heart failure. Several types of cells were reported to induce angiogenesis and cardiogenesis in vitro and in vivo. Circulating blood is an attractive and clinically feasible source to isolate stem or progenitor cells. Endothelial progenitor cells (EPC), which is one population of circulating progenitors, can differentiate to endothelial phenotype and can release several growth factors, which contributed to neovascularization in ischemic tissue. Indeed, several clinical trials showed beneficial effect of EPC on improvement of ischemia and cardiac function. Though cardiac differentiation of EPC was shown in vitro and in vivo, the rate was too low to explain the beneficial effects of cell therapy. Therefore, the elucidation of the mechanism, by which the expression of cardiac genes is induced, may help to design strategies to further enhance the repair capacity of the cells.
In vitro studies established that the presence of cardiomyocytes was required to induce cardiac differentiation of EPC suggesting that cell-to-cell contact would be indispensable for this process. Notch families of proteins are transmembrane receptors. After binding with their ligands, Notch intracellular domain (NICD) is cleaved and contributes to cardiovascular development. Notch activation was transiently detected in EPC as determined by immunhistochemical detection of the NICD and expression of human Notch target genes. Inhibition of γ-secretase blocked Notch cleavage and NICD translocation. Furthermore, the expression of the cardiac marker proteins were significantly suppressed by γ-secretase inhibition indicating that Notch activation facilitates cardiac marker gene expression. Because non-canonical Wnts have previously been shown to promote cardiac
differentiation, we additionally determined the influence of Notch activation on the expression of Wnt5a. Wnt5a expression was induced in the human cells by the co-culture and was blocked by γ-secretase inhibitor. Likewise, stimulation of Notch signaling by immobilized Jagged- 1 promoted Wnt5a expression in EPC. These data indicated that Notch and Wnts signaling contributed to cardiac differentiation of EPC. Importantly, Wnt5a pretreated EPC can differentiate to CM in vivo after myocardial infarction, suggesting this enhancing strategy might be suitable for cardiac repair.
However, the number and the functional capacity of EPC are impaired in patients with coronary artery disease. In contrast to adult cells, child cells might have better cell function. Therefore, we compared circulating progenitor cells isolated from children and from adults, and found that progenitor cells from children have a greater proliferative capacity which was significantly correlated with age. These cells expressed mesenchymal markers, and negative for hematopoietic marker CD45, have high telomerase activity and are positive for several stem cell markers (islet- 1, and Oct3/4) (figure Ie). The marker profiles of the clonally expanded cells is distinct from adult circulating "endothelial" progenitor cells (EPC), but resemble but are not identical as mesoangioblasts and unrestricted somatic stem cells (USSCs).
Since child progenitor cells additionally expressed several cardiac transcription factors (GATA4 and Nkx2.5), we investigated the capacity to differentiate into cardiomyocytes. After co-culture with neonatal rat cardiomyocytes, children-deribed progenitor cells expressed cardiac α-sarcomeric actinin. Moreover, co-culture of child progenitor cells with rat cardiomyocytes led to a higher expression of human troponin T, as assessed by human specific RT-PCR, as compared to EPC.
Furthermore, the intramyocardial injection of these progenitor cells into nude mice following myocardial infarction led to a significant functional improvement (LVEDP: - 20.3%, tau: -20.6%, LVEDV/weight -27.3%, vs control).
In summary, novel progenitor cells isolated from children have a greater proliferative and greater cardiomyocyte differentiation capacity than EPC, and improve cardiac function
after myocardial infarction. Therefore, these cells may be an alternative for the heart failure treatment.
EXAMPLE 4: Identification of a novel subset of multipotent circulating stem cells with a high capacity for cardiovascular regeneration
In Example 1 we identified circulating MAB-like cells in children. Children-derived MAB like cells (cMABs) showed vigorous proliferation capacity and high telomerase activity. Although, cMABs showed several stem cell features, the potential for cardiovascular repair and regeneration is not known.
Therefore, we assessed the lineage differentiation potential by culturing cMABs under conditions favouring endothelial cell (EC), smooth muscle cell (SMC) and cardiomyocyte (CM) differentiation. EC differentiation was determined by using matrigel assays (figure 2a/b). Tube like-structures were formed in vitro and in implanted matrigel plugs in vivo to a similar extent as compared to human umbilical cord endothelial cells (HUVEC). cMABs expressed endothelial markers and connected to the mouse vasculature leading to increased perfusion of the plugs (+133% increase). Consistent with the capacity of the cells to differentiate to the endothelial lineage, the transcription factors Hex and FIi-I known to play a key role in vascular development were highly expressed (figure 2c). Differentiation into SMC was achieved in individual cells by addition of TGFBl, while cultivation of the cells on jagged-coated dishes in combination with FGF8 induced the expression of SMC- specifϊc proteins in > 60 % of all cells. In order to induce differentiation into the cardiac lineage, cMABs were co-cultured with neonatal rat CM. After 6 days of co-culture, cMABs acquired a CM fate as demonstrated by the expression of α-sarcomeric actinin by immunohistocemistry (IHC) and by the expression of human troponin T (TnT) mRNA. Even in the absence of co-culture, incubation with Wnt3a, which was previously shown to promote CM differentiation of embryonic stem cells, increased the expression of Nkx 2.5, α-myosin heavy chain, and TnT. In line with these results, cells expressed various muscle transcription factors such as GATA-4, Mef-2C, while only some clones expressed Nkx2.5. Interestingly, cMABs strongly expressed Islet- 1, which was previously shown to make a
multipotent primordial cardiovascular progenitors. Taken together, cMABs are multipotent and can differentiate into the 3 distinct cardiovascular cell lineages.
In order to determine the potential functional benefit using cMABs for therapeutic applications, cells were injected in a nude mice model of hind limb ischemia. After 14 days, the recovery of blood flow was significantly greater in mice treated with cMABs compared to PBS-treated control mice. In addition, cMABs were injected in mice after induction of myocardial infarction. After 2 weeks, cell-treated mice exhibited a smaller infarct size and a significantly improved cardiac function with lower left ventricular end- diastolic pressures, and improved diastolic function (Tau) (LVEDP: -56.0%, Tau: -20.3%).
The in vivo differentiation of the injected cells to all three cardiovascular lineages was assessed by IHC.
In summary, cMABs differentiated to all three cardiovascular lineages in vitro and in vivo. Moreover, cMABs improved neovascularization and cardiac function after ischemia.
Given that these circulating cMABs can be easily isolated and expanded from peripheral blood, these cells might be suitable to augment cardiac repair in children with heart failure.
EXAMPLE 5: Detailed characterization of circulating mobilizable multipotent mesoangioblasts in humans
Blood-derived circulating mononuclear cells were obtained from children undergoing cardiopulmonary bypass for cardiac surgery. Cells were cultivated on fibronectin-coated dishes and first clones were detected after 1-2 weeks. Overall, 1.1 to 2.1 colonies were detected per ml blood after 2 weeks of culture. Cells showed a spindle-shaped morphology, exhibited a high proliferative capacity, and were cultured for 28.3+0.9 passages (Fig. IA). The proliferative capacity was closely correlated with the donor age (Fig. 1A/B) and was associated with a high telomerase activity, which was detected at least until the 15th passage (Fig. 1C). Onset of senescence as determined by acidic β-galactosidase staining started after the 20th passage (0.25 %) and approximately 10 % acidic β-galactosidase- positive cells were detected after 29 passages. Characterisation of the surface marker expression by flow cytometry and RT-PCR revealed that the cultivated cells express the
mesenchymal markers CD13, CD73, and CD44, the endothelial markers CD105, Tie2 and KDR, but were negative for the endothelial/hematopoietic marker CD31 and the hematopoietic markers CD34, CD133, and CD45 (Fig. ID and data not shown)). Table 2 provides a summary of the expression of various markers by RT-PCR and flow cytometry of the cultivated cells compared to other cells.
Table 2: Marker expressions (summary of FACS and RT-PCR)
Marker profiles of human umbilical vein endothelial cells (HUVEC), mesoangioblasts (MAB) from human aorta, CD34 positive cells, mesenchymal stem cells (MSC), children-derived MAB-like cells, and umbilical
cord blood-deπved cells are shown. Confirmed data by both FACS and RT-PCR are summarized. - , +, ++, +++ indicate no expression (0%), low expression (1-40%), high expression (40-80%), and highly expression (80-100%) by FACS measurement, respectively. Umbilical cord blood-deπved cells were obtained from umbilical cord blood by using same protocol as children-derived MAB-hke cells.
The high expression of KDR and Tie2 clearly distinguishes the isolated cells from mesenchymal stem cells (Table 2). Moreover, although the cells are CD105+KDR+, the absence of CD31 and lack of the hematopoietic markers CD34 and CD45 distinguish the cultivated children-derived cells from circulating endothelial and hematopoietic progenitor cells (Table 2 and (Ingram et al., Blood 104, 2752-60 (2004), Lin et al, J Clin Invest 105, 71-7 (2000), Timmermans et al., Arterioscler Thromb Vase Biol 27, 1572-9 (2007)). When comparing the marker expression profile to previously described cells, these children- derived cells resemble mesoangioblasts, which are multipotent progenitors of mesodermal tissue originally isolated from the embryonic dorsal aorta and characterised by the expression of mesenchymal and endothelial markers (Cossu and Bianco, Curr Opin Genet Dev 13, 537-42 (2003)). Consistent with the phenotype of mesoangioblasts isolated from adult tissue (Dellavalle et al., Nat Cell Biol 9, 255-67 (2007)), children-derived cells express the proteoglycan NG2, a marker for pericyte-derived cells.
Next, we characterized the expression of stem cell markers. Among the four factors Oct3/4, Klf4, c-myc and Sox2, which are sufficient to induce pluripotency in human fibroblasts (Takahashi et al., Cell 131, 861-72 (2007)), the children-derived mesoangioblast-like cells expressed Oct3/4, Klf4 and c-myc, while Sox2 expression was below the detection limit (Fig. 1E/F). In accordance, chromatin immunoprecipitation demonstrated that histone modifications associated with active transcription (histone H3 acetylation and H3 lysine 4 trimethylation) were present at the Oct3/4 and Klf4 promotor region, while heterochromatin modifications (trimethylated H3 lysine 9 and trimethylated H3 lysine 27) were low or absent . In contrast, the repressive histone modifications trimethyl-H3 lysine 27 was high at the Sox2 promotor (Fig. IG). The stem cell marker Nanog (Chambers et al., Cell 113, 643-55 (2003), K. Mitsui et al., Cell 113, 631-42 (2003)) was not detected (Fig. IE), whereas Sox 17, which was shown to be specifically expressed in fetal and neonatal hematopoietic stem cells (Kim, T. L. Saunders, S. J. Morrison, Cell 130, 470-83 (2007), was abundantly expressed (Fig. IE).
To elucidate whether the cells can be cloned on a single cell level, we performed limited dilution assays using cells from the 2nd -3rd passage. The clonal efficiency estimated by single cell deposition was 9.5+2.0 %. 18 expanded single cell-derived clones were further characterised and all clones showed the characteristic expression of CD73 and KDR, but lacked expression of CD45 (Fig 1F/G). The expression of stem cell markers like Oct3/4, Klf4 and Sox 17 was more heterogeneous (Fig. 1F/G). Collectively, these data indicate that in children undergoing cardiopulmonary bypass, the blood contains circulating mesoangioblast-like cells, which can be clonally expanded and express a variety of classical stem cell markers. To determine whether the cultured cells indeed originate from CD73+ circulating cells, we sorted CD73+ and CD73- cells from peripheral blood mononuclear cells before culturing the cells. The number of colonies was 10.3 times higher when CD73+ cells were used as starting population for the culture compared to nonsorted cells, while only very few colonies were occasionally observed in the CD73- fraction. These data suggest that the expression of CD73 indeed defines circulating mesoangioblast (cMAB).
Next, we assessed the lineage-directed differentiation potential by culturing the isolated cells under conditions favoring osteogenic, endothelial, smooth muscle and cardiomyocyte differentiation. After 2 weeks, osteogenic differentiation was detected, albeit at low frequency. Endothelial differentiation was determined by using matrigel assays. Tube like- structures were formed in vitro and in implanted matrigel plugs in vivo (Fig. 2B) to a similar extent as compared to human umbilical cord endothelial cells (FiUVEC). Implanted cells expressed endothelial markers and connected to the mouse vasculature leading to increased perfusion of the plugs. Consistent with the capacity of the cells to differentiate to the endothelial lineage, the transcription factors Hex and FIi-I, known to play a key role in vascular development (Guo et al., Blood 102, 2428-35 (2003), Hart et al., Immunity 13, 167-77 (2000)), were highly expressed (Fig. 2C). Differentiation into smooth muscle cells was achieved in individual cells by addition of TGFβl, while cultivation of the cells on jagged-coated dishes in combination with FGF8 induced the expression of smooth muscle- specific proteins in > 60 % of all cells. The mRNA expression of the muscle marker smooth muscle actin was additionally documented. Skeletal muscle differentiation was tested by co-culturing human mesoangioblasts with C2C12 mouse myogenic cells and
scoring the % of human nuclei fused into myotubes. More than 10% of human nuclei fused with mouse myoblasts indicating a significant myogenic potency, even though, as in embryonic mouse mesoangioblasts, spontaneous myogenesis did not occur (Minasi et al. 2002, supra). In order to induce differentiation into the cardiac lineage, cells were co- cultured with neonatal rat cardiomyocytes (Laugwitz et al., Nature 433, 647-53 (2005), Badorff et al., Circulation 107, 1024-32 (2003)). After 6 days of co-culture, children- derived cells acquired a cardiomyocyte fate as demonstrated by the expression of α- sarcomeric actinin by immunostaining, and by the expression of human troponin T mRNA. In order to exclude fusion, we co-cultured cells with paraformaldehyde-fixed cardiomyocytes. Again, human troponin T mRNA was detected (data not shown). Even in the absence of co-culture, incubation with Wnt3a, which was previously shown to promote cardiac differentiation of embryonic stem cells (Kwon et al., Proc Natl Acad Sci U S A 104, 10894-9 (2007), Naito et al., Proc Natl Acad Sci U S A 103, 19812-7 (2006)), increased the expression of α-myosin heavy chain (Fig. 2D). In line with these results, cells expressed various muscle transcription factors such as GAT A-4, Mef-2C, and Tbx5, while only some donors expressed Nkx2.5 (Fig. 2E). Interestingly, the children-derived cells strongly expressed Islet- 1 (Fig. 2E), which was previously shown to define a multipotent primordial cardiovascular progenitor (Laugwitz, supra). Taken together, the blood-derived mesoangioblast-like cells are multipotent and can be directed to differentiate into the 3 distinct cardiovascular cell lineages.
In order to determine the potential functional benefit using these multipotent circulating blood-derived cells for therapeutic applications, human cells were injected in a nude mice model of hind limb ischemia. After 14 days, the recovery of blood flow was significantly greater in mice treated with children-derived cells compared to PBS-treated control mice (Fig. 3A). In addition, cells were injected in mice after induction of myocardial infarction (Table 3).
Table 3: Characteristics and cardiac functional analysis of nude mice 2 weeks after myocardial infarction (MI) treated with PBS or MAB compared to sham controls
HR; heart rate, bpm; beat per minute, LVESP; left ventricle end-systolic pressure, LVEDP; left ventricle end- diastohc pressure * indicates p< 0.01 vs sham. # and ## indicates p< 0.05 and p<0.01 vs MI PBS group, respectively.
After 2 weeks, cell-treated mice exhibited a smaller infarct size and a significantly improved cardiac function with lower left ventricular end-diastolic pressures and improved diastolic function (Tau) (Fig. 3B/C). In addition, cells were injected intramyocardially in mice after induction of myocardial infarction. After 2 weeks, cell-treated mice exhibited a significantly, but modestly improved cardiac function with lower left ventricular end- diastolic pressures (46.2+11.0 % reduction) and improved diastolic function (Tau) (18.2+5.4 % reduction). The in vivo differentiation of the injected cells was assessed by immunostaining and RT-PCR. Injected cells differentiated to endothelial cells, smooth muscle cells, and cardiomyocytes (data not shown). Moreover, cardiac and endothelial differentiation was confirmed by human specific RT-PCR of troponin T and Tie2, respectively (Fig. 3D). Survival and retention of human cells was confirmed by human specific GAPDH expression, which was measured by quantitative PCR.In addition to the capacity of the injected cells to contribute to tissue regeneration in its pure sense by virtue of their differentiation to the cardiovascular cell lineages, cells express and secrete a variety of pro-angiogenic cytokines and cardioprotective factors known to contribute to improved infarct healing.
So far, due to ethical reasons, peripheral blood-derived cells from young donors had only been obtained from children undergoing cardiopulmonary bypass for cardiac surgery. Therefore, we questioned whether the mesoangioblast-like cells had been mobilized upon the stress induced by cardiopulmonary bypass and cardioplegia. Indeed, when we used blood without using cardiopulmonary bypass, the incidence of obtaining mesoangioblast- like cells was reduced (3 out of 10 patients). Moreover, in no incidence could we obtain
clonally expandable mesoangioblast-like cells form blood of adults not undergoing cardiopulmonary bypass. However, in adult patients (age 64-83 years) undergoing open heart surgery with cardiopulmonary bypass and cardioplegia, clonally expandable mesoangioblast-like cells were obtained from the blood of 5 out of 5 patients. Of note, the marker profile of all clones resembled mesoangioblasts (CD73+ KDR+ CD45', Fig. 4A), but was distinct from the previously reported CXCR4+ CD34+ cell populations shown to be mobilized in this patient cohort (Mieno et al., Circulation 114, 1186-92 (2006)). Thus, these data indicate that cardiopulmonary bypass and cardioplegia during open heart surgery contribute to mobilization of mesoangioblast-like cells into the blood of both children and adults.
In order to identify factors involved in the mobilization of mesoangioblast-like cells, we screened the profile of circulating cytokines before and after cardiopulmonary bypass (Fig. 4B/C). Out of the cytokines tested, hepatocyte growth factor (HGF) was most profoundly up-regulated (2.6+0.2-fold) during cardiopulmonary bypass. Since mesoangioblast-like cells abundantly express the HGF receptor, c-Met (Fig. 4D/E), we tested whether the administration of HGF can mobilize mesoangioblasts-like cells. 24 hours after intravenous injection of l μg/kg recombinant HGF into 8 weeks old Lewis rats, mesoangioblast-like clones were detected in 4 out of 5 rats, whereas clones were only detected in 4 out of 14 PBS- injected control rats. Moreover, the total number of clones was significantly higher in HGF-treated rats compared to controls (Fig. 4F). The marker profile of the expanded cells was similar to the human mesoangioblast-like cells (Fig. 4G) and CD45~CD73+KDR+ cells were detected by FACS (data not shown). Taken together, HGF appears to be involved in mobilizing mesoangioblast-like cells into the circulating blood.
Since out of the four pluripotency genes only Sox2 was completely silenced, we hypothesized that Sox2 transduction may enhance the multipotency of the cells. Therefore, we overexpressed Sox2 by lentiviral vectors and confirmed Sox2 expression by RT-PCR, qPCR and on protein level. Sox2-transduced cMAB demonstrated a re-expression of the pluripotency associated gene Nanog and an increase in Oct3/4, although the expression was still much lower compared to embryonic stem cells. In order to evaluate the potential of Sox2-transduced cMABs to generate progeny of the three germ layers, we induced
differentiaton in hepatocytes, neuronal cells in vitro according to published protocols (Lee et al., 2004 Hepatology 40, 1275-1284; Minasi et al., 2002, Development 129, 2773-2783; Romero-Ramos et al., 2002, J Neurosci Res 69, 894-907). Sox2-transduced cMABs efficiently differentiate to CKl 8 and α- fetoprotein expressing hepatocytes, and nestin- positive neuronal cells. Endothelial and cardiac differentiation was further quantified by using reporter gene assays, in which GFP is expressed under the control of the endothelial nitric oxide (eNOS) and α-myosine heavy chain (MHC) promoter, respectively. Sox2- transduced cMABs expressed eNOS-promoter driven GFP and formed vascular networks in vitro. Furthermore, Sox2-transduced cMABs showed a rapid and more efficient induction of αMHC-promoter driven GFP expression after co-culture with rat neonatal cardiomyocytes. Importantly, Sox2-transduced cMABs but not unmodified cMABs express MHC-promoter driven GFP when exposed to conditioned medium to induce cardiac differentiation. Differentiation to smooth muscle cells, which was very efficient in control cells (40 %) was further augmented when Sox2-l l transduced cMAB were exposed to TGFβ. Likewise skeletal myogenic differentiation was also increased, though not dramatically by Sox2 expression. These data document that Sox2-transduced cells have the potency to differentiate into all three germ layers in vitro, at variance with untransduced cells whose potency is more restricted to solid mesoderm.
In order to test whether Sox2-transduced cells exhibited improved therapeutic potential, we compared the effects of injecting Sox2-transduced cMABs in comparison to GFP- iransduced control cMABs in nude mice after induction of acute myocardial infarction. Whereas echocardiography confirmed that the infarct size at day 0 was similar in the groups, cardiac function was significantly improved in mice receiving Sox2- overexpressing cells compared to mice treated with GFP-transduced control cells after four weeks. Furthermore, administration of Sox2-overexpressing cells resulted in increased numbers of α- sarcomeric actinin, smooth muscle actin, and von Willebrand factor-positive human cells compared to the injection of GFP-transduced control cMAB as shown by immunostaining and quantitative PCR. To confirm cardiac differentiation, we transplanted Sox2-transduced cMABs expressing GFP under the control of the αMHC promoter. GFP- expressing α-sarcomeric actinin positive cells were detected in the border zone of the infarcts. These data suggest that Sox2 transduction enhances the cardiovascular repair
capacity as well as the ability to differentiate to endothelial, smooth muscle and cardiac cells. However, although Sox2-transduced cMAB formed embryoid body-like structures in vitro and differentiate to all three germ layers in vitro, we never observed teratoma formation when injecting Sox2-transduced cMABs into nude mice (N=12, 4 weeks observation). Likewise, spontaneously contracting embryoid bodies never developed in culture. These data indicate that, although Sox2 transduction led to re-expression of Nanog and increased the expression of Oct3/4, the expression levels of 12 pluripotency genes appear to be insufficient to reprogram cMAB to fully induced pluripotent cells (iPS) resembling embryonic stem cells.
In summary, our studies identify a novel subset of circulating human progenitor cells, which fulfils all criteria for a cell population to be used for cardiovascular regenerative therapeutic purposes: they are easily accessible in the peripheral blood, can be expanded in vitro to large numbers, are capable to differentiate into all three distinct cardiovascular cell lineages in vitro and in vivo, secrete pro-angiogenic and cardioprotective factors, and mediate significant functional improvements after therapeutic administration in models of ischemia and infarction, specifically when transduced with Sox2.
Claims
1. A mesoangioblast-like cell, obtained from a subject's blood, as a medicament, wherein the subject has been exposed to hepatocyte growth factor (HGF) or an agent elevating the subject's HGF level.
2. The mesoangioblast-like cell of claim 1, wherein the agent elevating the subject's HGF level is heparin or a functionally active derivate thereof.
3. The mesoangioblast-like cell of claim 1 or 2, (i) wherein the subject is an adult; and/or
(ii) wherein the subject is a mammal, particularly a human.
4. The mesoangioblast-like cell of any of claims 1 to 3, wherein the mesoangioblast- like cell is characterized by
- the presence of CD73 or KDR (VEGF-receptor-2), optionally also the presence of one or more markers selected from the group consisting of Oct3/4, Klf4, c- myc and Sox 17; and the absence of CD45, optionally also the absence CD34 or CD133, or
- the presence of KDR, CD73 and CD29 (and optionally also the presence of Oct3/4, Klf4, c-myc and/or Sox 17); and the absence of CD45, optionally also the absence CD34 or CD 133, or the presence of CD73 , CD 13 , CD44, CD 144, KDR and CD 105 and the absence of CD45, CD34 and CD133, or
- the presence of CD73, KDR and telomerase activity and the absence of CD45; or especially the presence of CD73 and KDR (VEGF-receptor-2), optionally also the presence CD44, Klf4, Oct3/4 and CD29, and the absence of CD45, optionally also the absence CD34 and CD133, or especially the presence of CD105, CD144, KDR, CD13, CD73, CD29 and CD44 and the absence of CD34, CD45, CD 133 and CD 18, or most preferably the presence of CD73, KDR (VEGF-receptor-2), Oct3/4, Klf4, c-myc and Sox 17, and the absence of CD45, CD34 and CD 133.
5. The mesoangioblast-like cell of any of claims 1 to 4, i) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to HGF and/or wherein the subject is exposed to 0.01 to 100 μg/kg bodyweight HGF; ii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin, and/or wherein the subject is exposed to 0.1 to
10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin; or iii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to a combination of (i) HGF and (ii) heparin or a functionally active derivative thereof, e.g. a low-molecular- weight heparin, and/or wherein the subject is exposed to (i) 0.01 to 100 μg/kg bodyweight HGF and (ii) 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin.
6. The mesoangioblast-like cell of any of claims 1 to 5, wherein the mesoangioblast- like cell is capable of differentiating into a mesoderm-derived cell, particularly into one, two or three cardiovascular lineage(s).
7. The mesoangioblast-like cell of any of claims 1 to 6 for the treatment of a cardiovascular disease and/or an ischemic disease, particularly wherein the cardiovascular and/or ischemic disease is selected from the group consisting of myocardial infarction, heart failure and peripheral vascular occlusive disease.
8. A method of isolating a mesoangioblast-like cell from a subject, comprising the steps of: a) exposing a subject to HGF and/or an agent elevating the subject's HGF level; and b) isolating a mesoangioblast-like cell mobilized by step a) from the subject.
9. A method of producing a mesoderm-derived cell, comprising the steps of: a) exposing a subject to HGF and/or an agent elevating the subject's HGF level; b) isolating a mesoangioblast-like cell mobilized by step a) from the subject; and c) differentiating the mesoangioblast-like cell into a mesoderm-derived cell.
10. The method of claim 8 or 9, wherein the mesoangioblast-like cell is further defined as in any of claims 2 to 5.
11. The method of any of claims 8 to 10, wherein the mesoderm-derived cell is an endothelial cell, a smooth muscle cell, a cardiomyocyte or an osteoblast.
12. The method of any of claims 8 to 11, wherein the mesoangioblast-like cell isolated in step b) is expanded, particularly clonally expanded.
13. The method of any of claims 9 to 12, wherein the differentiating of step c) is carried out by incubating the mesoangioblast-like cell in the presence of a differentiation factor.
14. Use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease, wherein the mesoangioblast-like cell has been obtained from a subject exposed to hepatocyte growth factor (HGF) and/or an agent elevating the subject's HGF level, particularly wherein the mesoangioblast is further defined as in any of claims 2 to 7.
15. A method of converting the mesoangioblast-like cell of any of the claims 1 to 6 into an inducible pluripotent stem cell-like cell, wherein the level of Sox2 protein in the mesoangioblast-like cell is increased, particularly wherein the increase is mediated by: a) transfecting the mesoangioblast-like cell of any of claims 1 to 6 with the Sox2 gene and expressing the same; b) transducing the mesoangioblast-like cell of any of claims 1 to 6 with the Sox2 protein; and/or c) activating a promoter directing the Sox2 gene expression in the mesoangioblast-like cell of any of claims 1 to 6.
16. A mesoangioblast-like cell, obtained from a subject's blood, as a medicament.
17. The mesoangioblast-like cell of claim 16, wherein the subject has been exposed to hepatocyte growth factor (HGF) or an agent elevating the subject's HGF level, particularly wherein the agent elevating the subject's HGF level is heparin or a functionally active derivate thereof.
18. The mesoangioblast-like cell of claim 16 or 17, (i) wherein the subject is an adult; and/or
(ii) wherein the subject is a mammal, particularly a human.
19. The mesoangioblast-like cell of any of claims 16 to 18, wherein the mesoangioblast- like cell is characterized by - the presence of CD73 or KDR (VEGF-receptor-2), optionally also the presence of one or more markers selected from the group consisting of Oct3/4, Klf4, c- myc and Sox 17; and the absence of CD45, optionally also the absence CD34 or CD133, or
- the presence of KDR, CD73 and CD29 (and optionally also the presence of Oct3/4, Klf4, c-myc and/or Soxl7); and the absence of CD45, optionally also the absence CD34 or CD133, or the presence of CD73, CD 13, CD44, CD 144, KDR and CD 105 and the absence of CD45, CD34 and CDl 33, or
- the presence of CD73, KDR and telomerase activity and the absence of CD45; or
- especially the presence of CD73 and KDR (VEGF-receptor-2), optionally also the presence CD44, Klf4, Oct3/4 and CD29, and the absence of CD45, optionally also the absence CD34 and CD133, or especially the presence of CD 105, CD 144, KDR, CD 13, CD73, CD29 and CD44 and the absence of CD34, CD45, CD 133 and CD 18, or most preferably the presence of CD73, KDR (VEGF-receptor-2), Oct3/4, Klf4, c-myc and Soxl7, and the absence of CD45, CD34 and CD133.
20. The mesoangioblast-like cell of any of claims 16 to 19, i) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to HGF and/or wherein the subject is exposed to 0.01 to 100 μg/kg bodyweight HGF; ii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin, and/or wherein the subject is exposed to 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin; or iii) the mesoangioblast-like cell has been isolated at least 1 h to 48 h after the subject's exposure to a combination of (i) HGF and (ii) heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin, and/or wherein the subject is exposed to (i) 0.01 to 100 μg/kg bodyweight HGF and (ii) 0.1 to 10 mg/kg bodyweight heparin or a functionally active derivative thereof, e.g. a low-molecular-weight heparin.
21. The mesoangioblast-like cell of any of claims 16 to 20, wherein the mesoangioblast- like cell is capable of differentiating into a mesoderm-derived cell, particularly into one, two or three cardiovascular lineage(s).
22. The mesoangioblast-like cell of any of claims 16 to 21 for the treatment of a cardiovascular disease and/or an ischemic disease, particularly wherein the cardiovascular and/or ischemic disease is selected from the group consisting of myocardial infarction, heart failure and peripheral vascular occlusive disease.
23. A method of isolating a mesoangioblast-like cell from a subject, comprising the steps of: a) exposing a subject to HGF and/or an agent elevating the subject's HGF level; and b) isolating a mesoangioblast-like cell mobilized by step a) from the subject.
24. A method of producing a mesoderm-derived cell, comprising the steps of: a) exposing a subject to HGF and/or an agent elevating the subject's HGF level; b) isolating a mesoangioblast-like cell mobilized by step a) from the subject; and c) differentiating the mesoangioblast-like cell into a mesoderm-derived cell.
25. The method of claim 23 or 24, wherein the mesoangioblast-like cell is further defined as in any of claims 17 to 20.
26. The method of any of claims 23 to 25, wherein the mesoderm-derived cell is an endothelial cell, a smooth muscle cell, a cardiomyocyte or an osteoblast.
27. The method of any of claims 23 to 26, wherein the mesoangioblast-like cell isolated in step b) is expanded, particularly clonally expanded.
28. The method of any of claims 24 to 27, wherein the differentiating of step c) is carried out by incubating the mesoangioblast-like cell in the presence of a differentiation factor.
29. A method of treating a recipient having a cardiovascular disease and/or an ischemic disease, wherein the mesoangioblast-like cell has been obtained from the blood of a subject, particularly wherein the mesoangioblast is further defined as in any of claims 17 to 22.
30. A method of converting the mesoangioblast-like cell of any of the claims 1 to 6 into an inducible pluripotent stem cell-like cell, wherein the level of Sox2 protein in the mesoangioblast-like cell is increased, particularly wherein the increase is mediated by: a) transfecting the mesoangioblast-like cell of any of claims 16 to 21 with the
Sox2 gene and expressing the same; b) transducing the mesoangioblast-like cell of any of claims 16 to 21 with the Sox2 protein; and/or c) activating a promoter directing the Sox2 gene expression in the mesoangioblast-like cell of any of claims 16 to 21.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2727053A CA2727053A1 (en) | 2008-06-26 | 2009-06-25 | Mesoangioblast-like cell as well as methods and uses relating thereto |
EP09769000A EP2318019A1 (en) | 2008-06-26 | 2009-06-25 | Mesoangioblast-like cell as well as methods and uses relating thereto |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13319208P | 2008-06-26 | 2008-06-26 | |
EP08011587A EP2138572A1 (en) | 2008-06-26 | 2008-06-26 | Mesoangioblast-like cell as well as methods and uses relating thereto |
US61/133,192 | 2008-06-26 | ||
EP08011587.6 | 2008-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009156151A1 true WO2009156151A1 (en) | 2009-12-30 |
Family
ID=39847087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/004584 WO2009156151A1 (en) | 2008-06-26 | 2009-06-25 | Mesoangioblast-like cell as well as methods and uses relating thereto |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100068190A1 (en) |
EP (2) | EP2138572A1 (en) |
CA (1) | CA2727053A1 (en) |
WO (1) | WO2009156151A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2683814A1 (en) * | 2011-03-11 | 2014-01-15 | National University of Singapore | Pericyte progenitors from peripheral blood |
WO2022196714A1 (en) | 2021-03-17 | 2022-09-22 | アステラス製薬株式会社 | Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein |
WO2023286832A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cells expressing vascular endothelial growth factor (vegf) at high level |
WO2023286834A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130209415A1 (en) * | 2010-06-03 | 2013-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Purified compositions of cardiovascular progenitor cells |
WO2012051515A2 (en) * | 2010-10-14 | 2012-04-19 | University Of Central Florida Research Foundation, Inc. | Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium |
WO2015002474A1 (en) * | 2013-07-03 | 2015-01-08 | 서울대학교병원 | Method for increasing stem-cell stemness in human cells |
GB201515820D0 (en) * | 2015-09-07 | 2015-10-21 | Ucl Business Plc | Tissue engineering |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
GB201708729D0 (en) * | 2017-06-01 | 2017-07-19 | Ucl Business Plc | Cryopreservation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007118680A2 (en) * | 2006-04-19 | 2007-10-25 | Ludwig-Maximilians-Universität München | Remedies for ischemia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020142457A1 (en) * | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
US7056738B2 (en) * | 2001-03-23 | 2006-06-06 | Tulane University | Early stage multipotential stem cells in colonies of bone marrow stromal cells |
-
2008
- 2008-06-26 EP EP08011587A patent/EP2138572A1/en not_active Ceased
-
2009
- 2009-06-25 US US12/491,844 patent/US20100068190A1/en not_active Abandoned
- 2009-06-25 EP EP09769000A patent/EP2318019A1/en not_active Withdrawn
- 2009-06-25 WO PCT/EP2009/004584 patent/WO2009156151A1/en active Application Filing
- 2009-06-25 CA CA2727053A patent/CA2727053A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007118680A2 (en) * | 2006-04-19 | 2007-10-25 | Ludwig-Maximilians-Universität München | Remedies for ischemia |
Non-Patent Citations (7)
Title |
---|
CIRCULATION, vol. 116, no. 16, Suppl. S, October 2007 (2007-10-01), 80TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; ORLANDO, FL, USA; NOVEMBER 04 -07, 2007, pages 166, ISSN: 0009-7322 * |
CIRCULATION, vol. 116, no. 16, Suppl. S, October 2007 (2007-10-01), 80TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; ORLANDO, FL, USA; NOVEMBER 04 -07, 2007, pages 210, ISSN: 0009-7322 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 2007 (2007-10-01), IWASAKI MASAYOSHI ET AL: "Circulating mesoangioblasts differentiate into cardiac myocytes and improve function after acute myocardial infarction", XP002501025, Database accession no. PREV200800197746 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 2007 (2007-10-01), KOYANAGI MASAMICHI ET AL: "Identification of a novel type of circulating progenitor cells resembling multipotent mesoangioblasts from peripheral blood of children", XP002501024, Database accession no. PREV200800197944 * |
GALLI DANIELA ET AL: "Mesoangioblasts, vessel-associated multipotent stem cells, repair the infarcted heart by multiple cellular mechanisms - A comparison with bone marrow progenitors, fibroblasts, and endothelial cells", ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 25, no. 4, April 2005 (2005-04-01), pages 692 - 697, XP002501023, ISSN: 1079-5642 * |
ISHIZAWA K ET AL: "Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 324, no. 1, 5 November 2004 (2004-11-05), pages 276 - 280, XP004605930, ISSN: 0006-291X * |
RUPP STEFAN ET AL: "Characterization of circulating stem/progenitor cells during postnatal human development", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 101, no. 5, 1 August 2007 (2007-08-01), pages E69, XP009106637, ISSN: 0009-7330 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2683814A1 (en) * | 2011-03-11 | 2014-01-15 | National University of Singapore | Pericyte progenitors from peripheral blood |
EP2683814A4 (en) * | 2011-03-11 | 2014-09-24 | Univ Singapore | Pericyte progenitors from peripheral blood |
US9809798B2 (en) | 2011-03-11 | 2017-11-07 | National University Of Singapore | Pericyte progenitors from peripheral blood |
WO2022196714A1 (en) | 2021-03-17 | 2022-09-22 | アステラス製薬株式会社 | Pericyte having basic fibroblast growth factor (bfgf) gene introduced therein |
WO2023286832A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cells expressing vascular endothelial growth factor (vegf) at high level |
WO2023286834A1 (en) | 2021-07-15 | 2023-01-19 | アステラス製薬株式会社 | Pericyte-like cell expressing vascular endothelial growth factor (vegf) at high level |
Also Published As
Publication number | Publication date |
---|---|
US20100068190A1 (en) | 2010-03-18 |
EP2138572A1 (en) | 2009-12-30 |
EP2318019A1 (en) | 2011-05-11 |
CA2727053A1 (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100068190A1 (en) | Mesoangioblast-like cell as well as methods and uses relating thereto | |
TWI698242B (en) | Methods of generating mesenchymal stromal cells using hemangioblasts | |
US10526581B2 (en) | Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof | |
US10358629B2 (en) | Regulating stem cells | |
US11660317B2 (en) | Compositions comprising cardiosphere-derived cells for use in cell therapy | |
AU2011299327B2 (en) | Tissue-specific differentiation matrices and uses thereof | |
JP2013510582A (en) | Spherical aggregate of mesenchymal stem cells | |
JP2010535468A (en) | Adult stem cell population derived from cardiac adipose tissue and its use in cardiac regeneration | |
JP7379452B2 (en) | Prevention of progressive heart failure | |
KR20140038236A (en) | Method for preparing mesenchymal stem cell aggregates | |
KR20170036105A (en) | Stem cell compositions and methods of producing stem cells for therapeutic applications | |
JPWO2004101775A1 (en) | Novel adult tissue-derived stem cells and uses thereof | |
JP2012532609A (en) | Heart tissue-derived cells | |
WO2011126264A2 (en) | Method for increasing activity in human stem cell | |
WO2021201286A1 (en) | High-potential pluripotent stem cells | |
US20200101117A1 (en) | Methods of cardiac repair | |
KR20220143092A (en) | Methods of treating chronic graft-versus-host disease | |
Schabort et al. | Potential myogenic stem cell populations: sources, plasticity, and application for cardiac repair | |
JP2021512654A (en) | Methods for Isolating Stem Cells from Tissues Under Thermal Conditions and Their Use | |
Svensson | Restoration of scarred vocal folds with stem cell implantation: Analyses in a xenograft model | |
WO2018003997A1 (en) | Prophylactic or therapeutic agent for organ fibrosis | |
Henning | Identification and characterisation of a novel, multi-potent, skeletal muscle-derived stem cell with broad developmental plasticity | |
Gnecchi et al. | Adult Stem Cell-Based Therapy for the Heart | |
Zhang et al. | A novel population of human bone marrow multipotent mesenchymal stem cells regenerates infarcted myocardium in rats | |
Theologou | Transcriptional profile of c-kit positive cardiac stem-progenitor cells (c-kitpos eCSCs) isolated from the four chambers of the adult human heart |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09769000 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2727053 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009769000 Country of ref document: EP |